{"version":3,"file":"shared-lib.DInOUZqG.mjs","names":["c","p"],"sources":["https:/framerusercontent.com/modules/Hs5UG1HWoXGH1QYQlogN/Hvp9RfmRw9dNyhHANYwN/SitePage.js"],"sourcesContent":["// DesignPeptide (designpeptide.com) site page. Generated by tools/build_purita_site.py; edit content/designpeptide.com/*.json, not this file.\n// One component, `page` prop picks the content. Header + body + cards + footer (notices are the last lines).\nimport{jsx as _jsx,jsxs as _jsxs}from\"react/jsx-runtime\";import{addPropertyControls,ControlType}from\"framer\";const SITE=\"DesignPeptide\";const KICKER=\"Peptide synthesis, purification and testing\";const NAV=[[\"/\",\"Home\"],[\"/guide/how-research-peptides-are-made-and-tested\",\"Guide\"],[\"/about\",\"About\"]];const FOOTER_NAV=[[\"/\",\"Home\"],[\"/guide/how-research-peptides-are-made-and-tested\",\"How research peptides are made and tested\"],[\"/articles/hplc-purity-vs-peptide-content\",\"HPLC purity vs net peptide content\"],[\"/articles/synthetic-peptide-impurities\",\"Common impurities in synthetic peptides and how labs detect them\"],[\"/articles/peptide-counterions-tfa-acetate-chloride\",\"TFA, acetate or chloride\"],[\"/articles/mass-spectrometry-esi-maldi-peptide-coa\",\"Mass spectrometry on a peptide COA\"],[\"/articles/aspartimide-formation-fmoc-spps\",\"Aspartimide formation in Fmoc peptide synthesis\"],[\"/about\",\"About\"],[\"/affiliate-disclosure\",\"Affiliate disclosure\"],[\"/research-only\",\"Research-only notice\"],[\"/privacy\",\"Privacy\"]];const PAGES={\"home\":{\"title\":\"Peptide design, synthesis and testing, explained\",\"path\":\"/\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<h2>What DesignPeptide covers</h2>\\n<p>DesignPeptide explains how research peptides are designed, synthesised, purified and tested. It also explains how to read the certificate of analysis (COA) that documents a batch. The pages cover chemistry and analytical methods only. They say nothing about the uses or effects of any compound.</p>\\n<ul>\\n<li><strong>Solid-phase synthesis.</strong> Merrifield\\'s 1963 paper introduced solid-phase peptide synthesis (SPPS). The growing chain is attached to an insoluble resin and built through repeated deprotection and coupling steps, with excess reagents washed away (<a href=\"https://www.scienceopen.com/document?vid=e6d73512-4877-46db-a0c4-17a8fe2d5bf7\">Merrifield, 1963, bibliographic record</a>).</li>\\n<li><strong>Purification and HPLC.</strong> As general analytical context, HPLC with a non-polar stationary phase separates peptide-related species by hydrophobicity, with UV detection commonly near 214 nm (220 nm is also used). Area-percent purity compares the peaks the detector can see. It is not necessarily the share of peptide by weight.</li>\\n<li><strong>Mass spectrometry.</strong> As general analytical context, MS supports identity by comparing expected and observed mass. It does not measure purity on its own, and it cannot tell apart every form with the same mass.</li>\\n<li><strong>Impurities.</strong> A review of related impurities in peptide medicines describes deletion and insertion sequences, incomplete deprotection, oxidation, deamidation and diastereomers (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25044089/\">D\\'Hondt et al., 2014, PubMed</a>). As general analytical context, side reactions such as racemisation during coupling and aspartimide formation at aspartic acid residues are also widely discussed in peptide chemistry.</li>\\n<li><strong>Certificates of analysis.</strong> What each field means, which details a useful report includes, and what a COA cannot show.</li>\\n</ul>\\n<h2>Who it is for</h2>\\n<p>The site is written for laboratory researchers, students of peptide chemistry and procurement staff who compare batch documents. Technical terms are defined where they first appear. Key claims are linked to sources where available, and points offered as general analytical context without a primary source are marked as such.</p>\\n<h2>Sourcing and documentation</h2>\\n<p>DesignPeptide does not sell peptides. The one research-use-only supplier mentioned is Purita, which publishes COA files for some of its products on its certificates page. Reports are available for some products but not every item, so check the page for the specific material. A mention is not a statement about product quality.</p>\\n<p>A COA describes only the sample tested and only the tests listed. A report showing HPLC and MS alone, for example, says nothing about water content, counter-ion content or endotoxin. Analytical work on seized falsified peptide products has found impurity profiles that the paperwork did not reveal (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30029448/\">Janvier et al., 2018, PubMed</a>). A clean-looking document is not the same as a confirmed result.</p>\\n<h2>Start here</h2>\\n<ol>\\n<li><a href=\"/guide/how-research-peptides-are-made-and-tested\">How research peptides are made and tested</a>: from resin to final report.</li>\\n<li><a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs peptide content</a>: why the two figures differ.</li>\\n<li><a href=\"/articles/synthetic-peptide-impurities\">Synthetic peptide impurities</a>: common types and how they are detected.</li>\\n<li><a href=\"/articles/peptide-counterions-tfa-acetate-chloride\">Peptide counterions</a>: TFA, acetate and chloride salts, and how they are measured.</li>\\n<li><a href=\"/articles/mass-spectrometry-esi-maldi-peptide-coa\">Mass spectrometry on a peptide COA</a>: how ESI-MS and MALDI-TOF confirm molecular mass and charge states.</li>\\n<li><a href=\"/articles/aspartimide-formation-fmoc-spps\">Aspartimide formation in Fmoc synthesis</a>: the side reaction at aspartic acid behind isoAsp and epimer impurities.</li>\\n<li><a href=\"/about\">About DesignPeptide</a>: the site\\'s scope and approach.</li>\\n</ol>\\n<h2>Supplier documentation</h2>\\n<p>Purita is a store that sells peptides for laboratory research use only. It publishes a certificates page where reports are available for some products; reports are not yet available for every item, so check the page for the specific material.</p>\\n<p><a href=\"https://puritapeptides.com/certificates?link_code=AUTO-200&amp;lid=82\" rel=\"sponsored nofollow\" target=\"_blank\">Visit the Purita website</a></p>\\n<p><em>Affiliate disclosure: this is a paid link. DesignPeptide earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</em></p>\\n<h2>Related pages</h2>\\n<ul>\\n<li><a href=\"/about\">About DesignPeptide</a></li>\\n<li><a href=\"/guide/how-research-peptides-are-made-and-tested\">How research peptides are made and tested: from synthesis to COA</a></li>\\n<li><a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content: two numbers that are often confused</a></li>\\n<li><a href=\"/articles/synthetic-peptide-impurities\">Common impurities in synthetic peptides and how labs detect them</a></li>\\n<li><a href=\"/articles/peptide-counterions-tfa-acetate-chloride\">TFA, acetate or chloride: why a peptide\\'s counterion matters</a></li>\\n<li><a href=\"/articles/mass-spectrometry-esi-maldi-peptide-coa\">Mass spectrometry on a peptide COA: how ESI-MS and MALDI-TOF confirm identity</a></li>\\n<li><a href=\"/articles/aspartimide-formation-fmoc-spps\">Aspartimide formation in Fmoc peptide synthesis: the side reaction behind isoAsp impurities</a></li>\\n</ul>',\"jsonld\":'[{\"@context\": \"https://schema.org\", \"@type\": \"WebSite\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"description\": \"How research peptides are synthesised, purified and tested, from solid-phase synthesis to HPLC, mass spectrometry, impurities and COAs.\", \"inLanguage\": \"en\", \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}}, {\"@context\": \"https://schema.org\", \"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\", \"logo\": \"https://framerusercontent.com/images/v39FXMoZ5n6Bf0tAgcB74udPrU.jpg\"}]',\"cover\":{\"src\":\"https://framerusercontent.com/images/v39FXMoZ5n6Bf0tAgcB74udPrU.jpg\",\"alt\":\"Abstract chain of linked coloured beads on a pale grid beside a stylised chromatogram peak\"},\"excerpt\":\"A plain guide to how research peptides are built, purified and analysed, and how to read the certificate of analysis that documents a batch.\",\"kind\":\"\"},\"about\":{\"title\":\"About DesignPeptide\",\"path\":\"/about\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<h2>About DesignPeptide</h2>\\n<p>DesignPeptide is an independent reference site about the chemistry of research peptides. It explains how they are designed, synthesised, purified and tested. It also explains how to read the certificate of analysis (COA) that documents a batch. The <a href=\"/guide/how-research-peptides-are-made-and-tested\">main guide</a> is a good place to begin.</p>\\n<h2>The Research Desk</h2>\\n<p>Pages are written by the DesignPeptide Research Desk, a small independent editorial group. The pages draw on primary literature and regulatory documents where these are available. Examples include Merrifield\\'s 1963 paper on solid-phase peptide synthesis (<a href=\"https://www.scienceopen.com/document?vid=e6d73512-4877-46db-a0c4-17a8fe2d5bf7\">bibliographic record</a>) and the FDA\\'s 2021 guidance on certain highly purified synthetic peptides (<a href=\"https://collections.nlm.nih.gov/txt/nlm:nlmuid-9918350982606676-pdf\">guidance text</a>). Sources are linked so that readers can verify them. Where no primary source is available, general background is identified as such.</p>\\n<h2>Scope and standards</h2>\\n<p>The site covers chemistry and analytical science only. Two examples are <a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity versus peptide content</a> and <a href=\"/articles/synthetic-peptide-impurities\">impurities in synthetic peptides</a>.</p>\\n<p>DesignPeptide gives no advice on the uses, amounts or administration of any peptide. Findings from studies and regulators are attributed to their source. They are described within the scope their authors stated. For example, the FDA\\'s 2021 impurity thresholds apply to a named group of products. They are not presented as a general rule for all peptides.</p>\\n<p>On this site, a COA is described as an analytical record. It is not presented as evidence that a material is suitable for any purpose.</p>\\n<h2>Corrections</h2>\\n<p>Errors can be reported to the Research Desk at the address given under Contact below (info@zvezdaff.com). Please include the page address and a short description of the problem. Where possible, include a supporting source. Confirmed errors are corrected, and substantive changes are dated on the page.</p>\\n<h2>Affiliate disclosure</h2>\\n<p>Some pages carry paid links to Purita, a research-use-only supplier. DesignPeptide may earn a commission on purchases made through those links. A link is not an endorsement. It is also not a statement about the quality of any product. Affiliate arrangements are disclosed on the pages where links appear. Full details are in the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</p>\\n<h2>Contact</h2>\\n<p>Corrections and other enquiries can be sent to the DesignPeptide Research Desk at <a href=\"mailto:info@zvezdaff.com\">info@zvezdaff.com</a>. Messages about factual errors are given priority, and a supporting source helps the Research Desk check a report quickly.</p>\\n<h2>Related pages</h2>\\n<ul>\\n<li><a href=\"/\">Peptide design, synthesis and testing, explained</a></li>\\n<li><a href=\"/guide/how-research-peptides-are-made-and-tested\">How research peptides are made and tested: from synthesis to COA</a></li>\\n<li><a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content: two numbers that are often confused</a></li>\\n<li><a href=\"/articles/synthetic-peptide-impurities\">Common impurities in synthetic peptides and how labs detect them</a></li>\\n</ul>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"AboutPage\", \"name\": \"About DesignPeptide\", \"description\": \"Who writes DesignPeptide, what the site covers, how corrections work, how affiliate links to Purita are disclosed, and how to get in touch.\", \"url\": \"https://designpeptide.com/about\", \"dateModified\": \"2026-10-21\", \"inLanguage\": \"en\", \"isPartOf\": {\"@type\": \"WebSite\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}}',\"cover\":{\"src\":\"https://framerusercontent.com/images/MhFSmGMGM8nWs03rxykIAxblvc.jpg\",\"alt\":\"Abstract layered shapes suggesting a peptide chain beside a stylised document outline\"},\"excerpt\":\"DesignPeptide is an independent reference site on peptide chemistry and analytical science, written by a small Research Desk. Scope, corrections, disclosure and contact.\",\"kind\":\"About\"},\"guide\":{\"title\":\"How research peptides are made and tested: from synthesis to COA\",\"path\":\"/guide/how-research-peptides-are-made-and-tested\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<h2>Overview</h2>\\n<p>A synthetic research peptide is assembled as a chain, released from a solid support and then analysed. The certificate of analysis (COA) records the test results for one batch. This guide covers chain assembly, by-products, counterions and the main quality-control tests. It ends with a COA checklist and a regulatory reference point. It describes chemistry and documentation only and makes no claims about the uses or effects of any compound.</p>\\n<p>Passages marked \"general context\" reflect widely used analytical practice, but the sources gathered for this guide do not include a primary reference for them.</p>\\n<h2>Building the chain: solid-phase synthesis</h2>\\n<p>In 1963 R. B. Merrifield described solid-phase peptide synthesis (SPPS) in the <em>Journal of the American Chemical Society</em>, using it to make a tetrapeptide (<a href=\"https://www.scienceopen.com/document?vid=e6d73512-4877-46db-a0c4-17a8fe2d5bf7\">bibliographic record</a>). The growing peptide is attached to an insoluble resin, and repeated rounds of deprotection and amino-acid coupling extend the chain. Because the peptide stays on the resin, excess reagents and by-products can be washed away between steps. This approach later made automated peptide production possible.</p>\\n<h2>Fmoc and Boc strategies</h2>\\n<p><em>General context.</em> Each incoming amino acid carries a temporary protecting group on its N-terminus, removed before the next coupling.</p>\\n<ul>\\n<li><strong>Boc chemistry</strong> removes the N-terminal group with acid, which usually calls for a resin and linker strategy suited to the acid conditions used for final cleavage.</li>\\n<li><strong>Fmoc chemistry</strong> removes its protecting group under basic conditions, commonly with piperidine, and often relies on acid for final cleavage from the resin.</li>\\n</ul>\\n<p>Neither strategy is better in every case. The choice depends on the sequence, the protecting groups, the resin and the intended product.</p>\\n<h2>Cleavage and by-products</h2>\\n<p>Once assembly is complete, the chain is cleaved from the resin. The crude material contains the target peptide along with related by-products. A review of related impurities in peptide medicines describes the main types: deletion and insertion sequences, incomplete deprotection, oxidation, deamidation and diastereomers (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25044089/\">D\\'Hondt et al., 2014, PubMed</a>).</p>\\n<p><em>General context</em> on how some of these arise:</p>\\n<ul>\\n<li><strong>Deletion and truncated sequences</strong> can follow a failed coupling or deprotection step, or early chain termination.</li>\\n<li><strong>Epimers</strong> can form by racemisation during activation or coupling and share the nominal mass of the intended peptide.</li>\\n<li><strong>Aspartimide-derived species</strong> come from a sequence- and condition-dependent side reaction at aspartic acid, which can yield isoAsp or epimerised forms.</li>\\n<li><strong>Oxidation</strong> commonly affects susceptible residues such as methionine, tryptophan or cysteine.</li>\\n</ul>\\n<p>These classes are covered further in <a href=\"/articles/synthetic-peptide-impurities\">synthetic peptide impurities</a>.</p>\\n<h2>Purification, drying and counterions</h2>\\n<p>The sources gathered here do not describe preparative RP-HPLC purification or freeze-drying (lyophilisation) in enough detail to support specific statements, so those steps are only named.</p>\\n<p>The finished solid is rarely pure peptide by weight. Its gross mass can include water, residual solvent, salts and counterions such as trifluoroacetate (TFA) or acetate, which matters when reading weight-based figures on a COA.</p>\\n<h2>Quality control tests</h2>\\n<p><em>General context</em> applies to every paragraph in this section.</p>\\n<p><strong>HPLC purity at 214 or 220 nm.</strong> RP-HPLC separates peptide-related species by hydrophobicity. UV detection near 214 nm is common because peptide bonds absorb strongly there; 220 nm is also used. Purity is usually an area percentage: the share of detected UV peak area assigned to the main peak, not the mass fraction of peptide. Co-elution, differing detector response and weakly absorbing impurities can all affect the figure.</p>\\n<p><strong>Mass spectrometry for identity.</strong> ESI-MS or MALDI-MS can confirm that the main component has the expected mass. MS supports identity, not purity, and a matching mass does not prove sequence order or distinguish every isomer.</p>\\n<p><strong>Net peptide content.</strong> This estimates how much of the weighed solid is peptide, after accounting for water, salts and counterions, and needs a separate test such as amino acid analysis. A batch can show high HPLC purity but lower peptide content, as explained in <a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs peptide content</a>.</p>\\n<p><strong>Water and residual solvents.</strong> Reported separately where relevant.</p>\\n<p><strong>Endotoxin.</strong> Bacterial endotoxin is generally assessed with a test based on Limulus amebocyte lysate (LAL). A meaningful result states units and the applicable limit, and method suitability and interference controls matter for the sample matrix. No compendial procedure or limit is cited here.</p>\\n<h2>A pharmaceutical reference point: FDA 2021 guidance</h2>\\n<p>In May 2021 the US Food and Drug Administration (FDA) issued guidance on abbreviated new drug applications (ANDAs) for certain highly purified synthetic peptides (<a href=\"https://collections.nlm.nih.gov/txt/nlm:nlmuid-9918350982606676-pdf\">guidance text</a>), also summarised in an FDA <a href=\"https://www.fda.gov/media/166572/download\">presentation</a> and <a href=\"https://www.fda.gov/media/166571/download\">summary</a>. Its scope is narrow: generic versions of glucagon, liraglutide, nesiritide, teriparatide and teduglutide, where the reference listed drug is of recombinant-DNA origin. For those products, the guidance:</p>\\n<ul>\\n<li>generally recommends identifying peptide-related impurities at 0.10% or more of the drug substance;</li>\\n<li>does not accept a new specified impurity above 0.5% for this approach;</li>\\n<li>expects new impurities from 0.10% to 0.5% to be characterised and justified, including consideration of safety, effectiveness and immunogenicity risk;</li>\\n<li>expects any impurity also found in the reference listed drug to be no higher than in that product.</li>\\n</ul>\\n<p>These thresholds are a benchmark for five named products, not a general specification for research-grade peptides or a standalone release limit.</p>\\n<h2>What a COA should contain</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Item</th>\\n<th>What to look for</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr>\\n<td>Material identification</td>\\n<td>Product name or sequence, batch/lot number, physical form</td>\\n</tr>\\n<tr>\\n<td>Identity</td>\\n<td>Method (e.g. ESI-MS), expected and observed mass</td>\\n</tr>\\n<tr>\\n<td>Purity</td>\\n<td>Result, method, wavelength, column and gradient or method reference, chromatogram</td>\\n</tr>\\n<tr>\\n<td>Peptide content</td>\\n<td>Result and basis of calculation, with any water or counterion correction</td>\\n</tr>\\n<tr>\\n<td>Counterion</td>\\n<td>Identity (e.g. TFA, acetate) and, where relevant, amount and method</td>\\n</tr>\\n<tr>\\n<td>Water and solvents</td>\\n<td>Results where applicable</td>\\n</tr>\\n<tr>\\n<td>Endotoxin</td>\\n<td>Result, units, method and limit, where controlled for the intended use</td>\\n</tr>\\n<tr>\\n<td>Specifications</td>\\n<td>Appearance, limits for each test, pass/fail outcome</td>\\n</tr>\\n<tr>\\n<td>Storage and dating</td>\\n<td>Storage conditions, test date, retest or expiry date</td>\\n</tr>\\n<tr>\\n<td>Issuer</td>\\n<td>Testing laboratory, issue date, authorised approval</td>\\n</tr>\\n</tbody>\\n</table>\\n<p>ICH Q7 (which defines a batch) and ICH Q2(R2) (on validating analytical procedures) are listed on the <a href=\"https://www.ich.org/page/quality-guidelines\">ICH quality guidelines page</a>. Some laboratories are accredited to <a href=\"https://www.iso.org/standard/66912.html\">ISO/IEC 17025</a> for a defined scope of tests.</p>\\n<h2>Limits of a COA</h2>\\n<p>A COA describes only the sample tested and only the tests listed; a report showing only HPLC and MS says nothing about water, counterion content or endotoxin. It is an analytical record, not evidence of suitability for any purpose, and a research-use COA is not automatically equivalent to a pharmaceutical drug-substance specification.</p>\\n<h2>Sources</h2>\\n<ul>\\n<li>Merrifield, \"Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide\", <em>JACS</em> (1963): <a href=\"https://www.scienceopen.com/document?vid=e6d73512-4877-46db-a0c4-17a8fe2d5bf7\">bibliographic record</a></li>\\n<li>D\\'Hondt et al., 2014, review of related impurities in peptide medicines: <a href=\"https://pubmed.ncbi.nlm.nih.gov/25044089/\">PubMed</a></li>\\n<li>FDA, ANDA guidance for certain highly purified synthetic peptide drug products (2021): <a href=\"https://collections.nlm.nih.gov/txt/nlm:nlmuid-9918350982606676-pdf\">guidance text</a></li>\\n<li>FDA presentation on the 2021 guidance: <a href=\"https://www.fda.gov/media/166572/download\">fda.gov</a></li>\\n<li>FDA summary of synthetic peptide guidance: <a href=\"https://www.fda.gov/media/166571/download\">fda.gov</a></li>\\n<li><a href=\"https://www.ich.org/page/quality-guidelines\">ICH quality guidelines</a></li>\\n<li><a href=\"https://www.iso.org/standard/66912.html\">ISO/IEC 17025</a></li>\\n</ul>\\n<h2>Supplier documentation</h2>\\n<p>Purita is a store that sells peptides for laboratory research use only. It publishes a certificates page where reports are available for some products; reports are not yet available for every item, so check the page for the specific material.</p>\\n<p><a href=\"https://puritapeptides.com/certificates?link_code=AUTO-200&amp;lid=82\" rel=\"sponsored nofollow\" target=\"_blank\">Visit the Purita website</a></p>\\n<p><em>Affiliate disclosure: this is a paid link. DesignPeptide earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</em></p>\\n<h2>Related pages</h2>\\n<ul>\\n<li><a href=\"/\">Peptide design, synthesis and testing, explained</a></li>\\n<li><a href=\"/about\">About DesignPeptide</a></li>\\n<li><a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content: two numbers that are often confused</a></li>\\n<li><a href=\"/articles/synthetic-peptide-impurities\">Common impurities in synthetic peptides and how labs detect them</a></li>\\n</ul>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"Article\", \"headline\": \"How research peptides are made and tested: from synthesis to COA\", \"description\": \"SPPS, Fmoc and Boc chemistry, counterions and QC tests explained, with a checklist of what a peptide certificate of analysis should contain.\", \"image\": [\"https://framerusercontent.com/images/4Onia9xeIUiImNJVCAKhiLdcSo.jpg\"], \"datePublished\": \"2026-10-21\", \"dateModified\": \"2026-10-21\", \"inLanguage\": \"en\", \"author\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide Research Desk\", \"url\": \"https://designpeptide.com/about\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}, \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https://designpeptide.com/guide/how-research-peptides-are-made-and-tested\"}, \"isAccessibleForFree\": true}',\"cover\":{\"src\":\"https://framerusercontent.com/images/4Onia9xeIUiImNJVCAKhiLdcSo.jpg\",\"alt\":\"Abstract illustration of a chain of linked beads on a lattice beside a stylised chromatogram trace\"},\"excerpt\":\"How synthetic research peptides are assembled and analysed, and what each section of a certificate of analysis records.\",\"date\":\"21 October 2026\",\"kind\":\"Guide\"},\"hplc-purity-vs-peptide-content\":{\"title\":\"HPLC purity vs net peptide content: two numbers that are often confused\",\"path\":\"/articles/hplc-purity-vs-peptide-content\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<p><em>Published 21 October 2026</em></p>\\n<h2>Two questions, two numbers</h2>\\n<p>A certificate of analysis (COA) for a synthetic peptide often carries two figures that look alike but answer different questions. <strong>HPLC purity</strong> asks what share of the material the detector can see belongs to the main peak. <strong>Net peptide content</strong> asks how much of the weighed powder is actually peptide.</p>\\n<p>The gross mass of a peptide powder can include water, residual solvent, salts and counterions. A batch can therefore show high chromatographic purity and still have a lower peptide content by weight. For background on how batches are made and tested, see the <a href=\"/guide/how-research-peptides-are-made-and-tested\">guide to how research peptides are made and tested</a>.</p>\\n<h2>What area-percent purity measures</h2>\\n<p>High-performance liquid chromatography (HPLC) passes a dissolved sample through a column. For peptides this normally means a column with a non-polar stationary phase, which separates peptide-related species by hydrophobicity. A detector records each component as a peak on a chromatogram.</p>\\n<p>The purity figure is the area of the main peak as a percentage of the total detected peak area. It is a <strong>relative</strong> figure that compares peaks with one another. It is not the peptide\\'s mass fraction and not a measure of the total chemical content of the sample.</p>\\n<h2>Detection wavelength</h2>\\n<p>Most peptide methods use ultraviolet (UV) detection. A wavelength near 214 nm is common because peptide bonds absorb strongly there, and 220 nm is also used. The chromatogram only shows what absorbs at the chosen setting, so a purity figure given without its wavelength is missing part of the information needed to interpret it.</p>\\n<h2>Co-elution and response factors</h2>\\n<p>Two effects limit what an area percentage can show.</p>\\n<ul>\\n<li><strong>Co-elution.</strong> Closely related impurities can leave the column at the same time as the main peak and be counted as part of it. A review of related impurities in peptide medicines describes the main types, including deletion and insertion sequences, incomplete deprotection, oxidation, deamidation and diastereomers (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25044089/\">D\\'Hondt et al., 2014, PubMed</a>). Some, such as epimers, share the nominal mass of the target. Their origins are covered on the <a href=\"/articles/synthetic-peptide-impurities\">synthetic peptide impurities</a> page.</li>\\n<li><strong>Response factors.</strong> Different compounds do not absorb UV light equally. A weakly absorbing impurity gives a smaller peak than its true amount would suggest; a strongly absorbing one gives a larger peak. Area percent quietly assumes similar responses, which is not always the case.</li>\\n</ul>\\n<h2>Net peptide content, counterions and water</h2>\\n<p>The gross mass of a peptide powder can include water, residual solvent, salts and counterions such as trifluoroacetate (TFA), which is left over from purification, or acetate. These components do not show up in the UV chromatogram the way the peptide does, so they do not register in the purity figure in the same way, while still adding to the weighed mass.</p>\\n<p>Net peptide content (also called peptide content or assay, depending on the method) needs a separate measurement, such as amino acid analysis. A COA that reports it should state the basis of calculation and any correction for water or counterions.</p>\\n<h2>Reading both on a COA</h2>\\n<p>Points worth checking on a peptide COA:</p>\\n<ol>\\n<li><strong>Purity:</strong> the result, method, detection wavelength and chromatographic conditions or a method reference. An attached chromatogram says more than a single number.</li>\\n<li><strong>Peptide content or assay:</strong> whether it is reported at all, the method and the basis of calculation.</li>\\n<li><strong>Counterion and water:</strong> the counterion named and, where relevant, quantified; water content and residual solvents stated where applicable.</li>\\n<li><strong>Identity:</strong> a mass spectrometry result with expected and observed mass. MS supports identity, not purity, and cannot distinguish all isomers.</li>\\n</ol>\\n<p>A report showing only HPLC and MS says nothing about water, counterion content or the peptide fraction of the powder.</p>\\n<h2>Worked example (illustrative)</h2>\\n<p>The figures below are invented to show the arithmetic. They do not describe any real batch.</p>\\n<p>A COA lists <strong>HPLC purity 98%</strong> and <strong>net peptide content 80%</strong>.</p>\\n<ul>\\n<li>Take 100 parts by weight of the powder as received.</li>\\n<li>Net peptide content indicates about 80 of those parts are peptide material.</li>\\n<li>The other 20 parts are non-peptide mass. In this made-up case, imagine roughly 12 parts counterion, 6 parts water and 2 parts residual solvent and salts.</li>\\n<li>The 98% purity figure applies to the UV-visible peptide-related material. If, as a simplifying assumption, peak area tracked mass among those species, about 98% of the 80 parts would be the target sequence: roughly 78 parts, with about 2 parts of detected peptide-related impurities.</li>\\n</ul>\\n<p>So a batch labelled \"98% pure\" could be closer to 78% target peptide by weight. Neither figure is wrong; they measure different things. The 78-part estimate rests on the response-factor assumption and on how the content method counts related impurities, so it is an approximation, not a result.</p>\\n<h2>Limitations</h2>\\n<ul>\\n<li><strong>Both figures depend on method.</strong> Whether an HPLC method can separate and detect the relevant impurities is a question of validation. The ICH Q2(R2) guideline on validating analytical procedures, listed on the <a href=\"https://www.ich.org/page/quality-guidelines\">ICH quality guidelines page</a>, covers specificity, accuracy and precision.</li>\\n<li><strong>A COA describes the sample tested.</strong> It says something about other containers only if they come from the same, uniform batch.</li>\\n<li><strong>Regulatory thresholds are product-specific.</strong> FDA\\'s May 2021 guidance on certain highly purified synthetic peptides referring to listed drugs of rDNA origin (glucagon, liraglutide, nesiritide, teriparatide and teduglutide) generally recommends identifying peptide-related impurities at 0.10% or greater, and states that a new specified impurity above 0.5% is not acceptable for that approach (<a href=\"https://collections.nlm.nih.gov/txt/nlm:nlmuid-9918350982606676-pdf\">FDA guidance text</a>; <a href=\"https://www.fda.gov/media/166572/download\">FDA presentation</a>). These numbers apply to that narrow scope, not to every peptide.</li>\\n<li><strong>Paperwork is not confirmation.</strong> Analytical work on seized falsified peptide products found impurity profiles that the documents did not reveal (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30029448/\">Janvier et al., 2018, PubMed</a>).</li>\\n<li><strong>A research-use COA is not a drug-substance specification.</strong> It is an analytical record and says nothing about suitability for any use.</li>\\n</ul>\\n<h2>Supplier documentation</h2>\\n<p>Purita is a store that sells peptides for laboratory research use only. It publishes a certificates page where reports are available for some products; reports are not yet available for every item, so check the page for the specific material.</p>\\n<p><a href=\"https://puritapeptides.com/certificates?link_code=AUTO-200&amp;lid=82\" rel=\"sponsored nofollow\" target=\"_blank\">Purita certificates page</a></p>\\n<p><em>Affiliate disclosure: this is a paid link. DesignPeptide earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</em></p>\\n<h2>Related pages</h2>\\n<ul>\\n<li><a href=\"/\">Peptide design, synthesis and testing, explained</a></li>\\n<li><a href=\"/about\">About DesignPeptide</a></li>\\n<li><a href=\"/guide/how-research-peptides-are-made-and-tested\">How research peptides are made and tested: from synthesis to COA</a></li>\\n<li><a href=\"/articles/synthetic-peptide-impurities\">Common impurities in synthetic peptides and how labs detect them</a></li>\\n</ul>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"Article\", \"headline\": \"HPLC purity vs net peptide content: two numbers that are often confused\", \"description\": \"Why HPLC area-percent purity and net peptide content measure different things, and how to read both on a peptide certificate of analysis.\", \"image\": [\"https://framerusercontent.com/images/SEt3Kzd1lUgNAwtkxDdjOVG9Jo.jpg\"], \"datePublished\": \"2026-10-21\", \"dateModified\": \"2026-10-21\", \"inLanguage\": \"en\", \"author\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide Research Desk\", \"url\": \"https://designpeptide.com/about\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}, \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https://designpeptide.com/articles/hplc-purity-vs-peptide-content\"}, \"isAccessibleForFree\": true}',\"cover\":{\"src\":\"https://framerusercontent.com/images/SEt3Kzd1lUgNAwtkxDdjOVG9Jo.jpg\",\"alt\":\"Abstract chromatogram peaks beside a segmented bar showing the parts of a weighed powder\"},\"excerpt\":\"In an illustrative example, a batch shows 98% HPLC purity yet only 80% peptide by weight. This page explains why the two figures differ and how to read each on a COA.\",\"date\":\"21 October 2026\",\"kind\":\"Article\"},\"synthetic-peptide-impurities\":{\"title\":\"Common impurities in synthetic peptides and how labs detect them\",\"path\":\"/articles/synthetic-peptide-impurities\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<p><em>Published 21 October 2026</em></p>\\n<h2>Why impurities appear</h2>\\n<p>Merrifield\\'s 1963 paper introduced solid-phase peptide synthesis (SPPS). In SPPS the growing chain is attached to an insoluble resin and built through repeated deprotection and coupling steps. Excess reagents and by-products can be washed away between steps. The approach later enabled automated peptide production (<a href=\"https://www.scienceopen.com/document?vid=e6d73512-4877-46db-a0c4-17a8fe2d5bf7\">Merrifield, 1963, bibliographic record</a>).</p>\\n<p>The following is general background rather than a claim drawn from a specific source. When a step does not run to completion, or a side reaction occurs, the crude product contains the target peptide alongside closely related molecules. Purification aims to reduce these, and the analytical tests described below are how laboratories look for what remains.</p>\\n<p>The wider workflow is covered in the <a href=\"/guide/how-research-peptides-are-made-and-tested\">guide to how research peptides are made and tested</a>.</p>\\n<h2>The main impurity types</h2>\\n<p><strong>Deletion and truncated sequences.</strong> A deletion sequence lacks one or more amino acids because a coupling or deprotection step failed. A truncated sequence stopped growing early. Both are chemically very similar to the target, and UV detection alone may not distinguish them from it. A review of related impurities in peptide medicines lists the main types as deletion and insertion sequences, incomplete deprotection, oxidation, deamidation and diastereomers (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25044089/\">D\\'Hondt et al., 2014, PubMed</a>).</p>\\n<p><strong>Racemisation and epimers.</strong> During activation or coupling, a residue can partly convert to its mirror-image form. The result is an epimer with the same nominal mass as the intended peptide. Because the mass is unchanged, MS alone cannot distinguish some epimers, and chromatographic separation is needed as evidence.</p>\\n<p><strong>Aspartimide formation.</strong> This side reaction involves aspartic acid, and how far it occurs depends on the sequence and the reaction conditions. Subsequent products can include isoaspartate (isoAsp) variants and epimerised forms.</p>\\n<p><strong>Oxidation.</strong> Methionine, tryptophan and cysteine are commonly affected. Oxidation can produce characteristic mass shifts, but interpreting those shifts still needs chromatographic or other orthogonal evidence.</p>\\n<p><strong>Residual TFA, solvents and water.</strong> Trifluoroacetate (TFA) is often left over from purification as a counterion; acetate is another common counterion. Weighed material can also contain water, residual solvent and salts. These do not register in the same way as the peptide on a UV chromatogram, so a sample can show high chromatographic purity but a lower peptide content by weight. This difference is explained in <a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity versus peptide content</a>.</p>\\n<p><strong>Aggregation.</strong> Aggregation, in which peptide molecules associate into larger species, is a further quality attribute sometimes discussed for peptides. The sources used for this page do not describe how aggregates are detected or set limits for them, so it is noted here without further detail.</p>\\n<h2>Which method detects what</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Method</th>\\n<th>Measures</th>\\n<th>Tends to reveal</th>\\n<th>Main limitation</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr>\\n<td>RP-HPLC, UV near 214 or 220 nm</td>\\n<td>Separation by hydrophobicity; peak areas</td>\\n<td>Deletion and truncated sequences, oxidised forms and some epimers, where chromatographically resolved</td>\\n<td>Co-elution, differing response factors, weakly absorbing impurities; area percent is not mass fraction</td>\\n</tr>\\n<tr>\\n<td>MS (ESI-MS, MALDI-MS)</td>\\n<td>Molecular mass</td>\\n<td>Expected mass of the main component; mass-shifted species</td>\\n<td>Cannot prove sequence order or separate all same-mass isomers</td>\\n</tr>\\n<tr>\\n<td>Tandem MS (MS/MS) or sequencing</td>\\n<td>Fragmentation linked to sequence</td>\\n<td>Supporting evidence for residue order</td>\\n<td>Adds confidence rather than replacing chromatography</td>\\n</tr>\\n<tr>\\n<td>Amino acid analysis</td>\\n<td>Amount of peptide present</td>\\n<td>Net peptide content by weight</td>\\n<td>A separate measurement from HPLC purity</td>\\n</tr>\\n<tr>\\n<td>Counterion, water and solvent tests</td>\\n<td>Non-peptide components</td>\\n<td>TFA or acetate, water, solvents</td>\\n<td>Only informative if actually run</td>\\n</tr>\\n</tbody>\\n</table>\\n<p>UV detection near 214 nm is common because peptide bonds absorb strongly there; 220 nm is also used. A reported area-percent purity is the share of detected UV peak area assigned to the main peak. It is not necessarily the peptide\\'s mass fraction or total chemical content.</p>\\n<p>In short, HPLC supports purity and MS supports identity. A report that shows only one of the two leaves a gap.</p>\\n<h2>The FDA 2021 thresholds and their limited scope</h2>\\n<p>The figures 0.10% and 0.5% come from a May 2021 FDA guidance on abbreviated new drug applications (ANDAs) for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant-DNA origin (<a href=\"https://collections.nlm.nih.gov/txt/nlm:nlmuid-9918350982606676-pdf\">FDA guidance text</a>). Its scope is narrow: glucagon, liraglutide, nesiritide, teriparatide and teduglutide.</p>\\n<p>For those products, the guidance text states the following:</p>\\n<ul>\\n<li>The FDA generally recommends identifying peptide-related impurities at 0.10% or more of the drug substance.</li>\\n<li>A new specified impurity above 0.5% is described as not acceptable for that approach.</li>\\n<li>New impurities from 0.10% through 0.5% are to be characterised and justified, including consideration of safety, effectiveness and immunogenicity risk.</li>\\n<li>Impurities also present in the reference listed drug should be at a level no higher than in the reference product.</li>\\n</ul>\\n<p>The FDA has also published a summary of this guidance and related product-specific guidances (<a href=\"https://www.fda.gov/media/166571/download\">FDA summary</a>), and an FDA presentation on common deficiencies repeats these points (<a href=\"https://www.fda.gov/media/166572/download\">FDA presentation</a>).</p>\\n<p>These thresholds are not a universal specification for synthetic peptides, and they are not a standalone release limit. They do not automatically apply to research-use materials.</p>\\n<h2>Reading a COA with impurities in mind</h2>\\n<p>A more informative certificate of analysis includes:</p>\\n<ul>\\n<li>The HPLC method, detection wavelength and conditions, with the chromatogram attached.</li>\\n<li>The expected and observed mass.</li>\\n<li>The peptide content and the basis on which it was calculated.</li>\\n<li>The identity of the counterion.</li>\\n<li>Water and solvent results where relevant.</li>\\n</ul>\\n<p>A COA covers only the tests it lists and only the sample tested. Whether a method can separate the relevant impurities is a matter of validation; the ICH Q2(R2) guideline on validating analytical procedures, listed on the <a href=\"https://www.ich.org/page/quality-guidelines\">ICH quality guidelines page</a>, describes what that involves. Analysis of seized falsified peptide products has found impurity profiles that the accompanying paperwork did not reveal (<a href=\"https://pubmed.ncbi.nlm.nih.gov/30029448/\">Janvier et al., 2018, PubMed</a>).</p>\\n<h2>Sources</h2>\\n<ul>\\n<li>Merrifield, <em>JACS</em> (1963): <a href=\"https://www.scienceopen.com/document?vid=e6d73512-4877-46db-a0c4-17a8fe2d5bf7\">bibliographic record</a></li>\\n<li>D\\'Hondt et al., 2014: <a href=\"https://pubmed.ncbi.nlm.nih.gov/25044089/\">PubMed</a></li>\\n<li>Janvier et al., 2018: <a href=\"https://pubmed.ncbi.nlm.nih.gov/30029448/\">PubMed</a></li>\\n<li>FDA, ANDAs for certain highly purified synthetic peptide drug products (2021): <a href=\"https://collections.nlm.nih.gov/txt/nlm:nlmuid-9918350982606676-pdf\">guidance text</a></li>\\n<li>FDA summary of synthetic peptide guidance: <a href=\"https://www.fda.gov/media/166571/download\">download</a></li>\\n<li>FDA presentation on common deficiencies: <a href=\"https://www.fda.gov/media/166572/download\">download</a></li>\\n<li>ICH quality guidelines: <a href=\"https://www.ich.org/page/quality-guidelines\">ICH</a></li>\\n</ul>\\n<h2>Supplier documentation</h2>\\n<p>Purita is a store that sells peptides for laboratory research use only. It publishes a certificates page where reports are available for some products; reports are not yet available for every item, so check the page for the specific material.</p>\\n<p><a href=\"https://puritapeptides.com/certificates?link_code=AUTO-200&amp;lid=82\" rel=\"sponsored nofollow\" target=\"_blank\">Purita certificates page</a></p>\\n<p><em>Affiliate disclosure: this is a paid link. DesignPeptide earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</em></p>\\n<h2>Related pages</h2>\\n<ul>\\n<li><a href=\"/\">Peptide design, synthesis and testing, explained</a></li>\\n<li><a href=\"/about\">About DesignPeptide</a></li>\\n<li><a href=\"/guide/how-research-peptides-are-made-and-tested\">How research peptides are made and tested: from synthesis to COA</a></li>\\n<li><a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content: two numbers that are often confused</a></li>\\n</ul>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"Article\", \"headline\": \"Common impurities in synthetic peptides and how labs detect them\", \"description\": \"Deletion sequences, epimers, aspartimide, oxidation, residual TFA and solvents: where they come from, which tests find them and what FDA thresholds cover.\", \"image\": [\"https://framerusercontent.com/images/B2NjNZ7krmvdDvi2lgMhX6JMM.jpg\"], \"datePublished\": \"2026-10-21\", \"dateModified\": \"2026-10-21\", \"inLanguage\": \"en\", \"author\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide Research Desk\", \"url\": \"https://designpeptide.com/about\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}, \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https://designpeptide.com/articles/synthetic-peptide-impurities\"}, \"isAccessibleForFree\": true}',\"cover\":{\"src\":\"https://framerusercontent.com/images/B2NjNZ7krmvdDvi2lgMhX6JMM.jpg\",\"alt\":\"Abstract illustration of chromatogram peaks beside a chain of linked coloured beads, one bead out of place\"},\"excerpt\":\"The impurities that arise in synthetic peptides, the analytical methods that reveal them, and the narrow scope of the FDA's 2021 impurity thresholds.\",\"date\":\"21 October 2026\",\"kind\":\"Article\"},\"peptide-counterions-tfa-acetate-chloride\":{\"title\":\"TFA, acetate or chloride: why a peptide's counterion matters\",\"path\":\"/articles/peptide-counterions-tfa-acetate-chloride\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<p><em>Published 22 October 2026</em></p>\\n<h2>Where the TFA comes from</h2>\\n<p>In solid-phase peptide synthesis (SPPS), the finished chain is cut from the resin with trifluoroacetic acid (TFA), and TFA is also the usual acidic additive in the RP-HPLC used to purify it. Free TFA is largely removed when the product is freeze-dried. TFA bound to positively charged groups is not. Basic residues such as lysine, arginine and histidine, and the free N-terminus, pair with trifluoroacetate anions, so cationic peptides are typically obtained as TFA salts (<a href=\"https://pubmed.ncbi.nlm.nih.gov/18035848/\">Roux et al., 2008, PubMed</a>).</p>\\n<p>The number of TFA molecules per peptide molecule depends on how many cationic sites the sequence has. The counterion is part of the weighed solid, which is one reason HPLC purity and net peptide content differ. That difference is explained in <a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content</a>.</p>\\n<h2>Why the counterion can change an experiment</h2>\\n<p>TFA has long been suspected of interfering with biological assays, and two studies are often cited.</p>\\n<ul>\\n<li><strong>Cell proliferation.</strong> <a href=\"https://pubmed.ncbi.nlm.nih.gov/10567002/\">Cornish et al. (1999)</a> reported that TFA at nanomolar concentrations reduced cell numbers in fetal rat osteoblast and chondrocyte cultures. When they compared TFA and hydrochloride salts of amylin, amylin-(1-8) and calcitonin, the TFA salts consistently showed less proliferation. The authors warned this could lead researchers to miss an effect or to report an antiproliferative effect that the peptide does not have.</li>\\n<li><strong>A 2026 mouse study.</strong> <a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC13635227/\">Tang et al. (2026), <em>Nature Communications</em></a> reported that TFA itself is bioactive in mice and cultured liver cells. They found peroxisome proliferation and changes in lipid metabolism, with evidence that TFA binds the nuclear receptor PPAR-α. The effects appeared with TFA alone and with TFA present as the counterion of several short, unrelated peptides. The authors conclude that the contribution of TFA needs to be assessed in some studies that use synthetic peptides. Their institution has filed a patent application on uses of TFA, which the paper discloses.</li>\\n</ul>\\n<p>Effects of counterions are not one-directional. In a comparison of five antimicrobial peptides prepared as TFA, acetate and hydrochloride salts, the salt form changed antibacterial activity, red-cell lysis and cytotoxicity, but the pattern differed from peptide to peptide (<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5917001/\">Sikora et al., 2018, PMC</a>). For that reason, the counterion is best handled as an experimental variable, not assumed to be inert.</p>\\n<h2>The common salt forms</h2>\\n<table>\\n<thead>\\n<tr>\\n<th>Counterion</th>\\n<th>Typical origin</th>\\n<th>Notes from the literature</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr>\\n<td>Trifluoroacetate (TFA)</td>\\n<td>Default after TFA cleavage and RP-HPLC purification</td>\\n<td>Can interfere with infrared characterisation and with some cell and animal studies</td>\\n</tr>\\n<tr>\\n<td>Acetate</td>\\n<td>Exchange step, or purification with acetic acid buffers</td>\\n<td>Most approved peptide drugs are acetate salts; exchange runs under milder conditions than HCl exchange</td>\\n</tr>\\n<tr>\\n<td>Chloride (hydrochloride)</td>\\n<td>Exchange by repeated freeze-drying from dilute HCl</td>\\n<td>HCl is a stronger acid than TFA, so it can displace it; very low pH can degrade some peptides</td>\\n</tr>\\n</tbody>\\n</table>\\n<p>The acetate and chloride notes are drawn from a review of counterions in peptides, which also notes that a few marketed peptide drugs, such as bivalirudin, are formulated as trifluoroacetates (<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7761850/\">Sikora et al., 2020, PMC</a>).</p>\\n<h2>How labs exchange TFA</h2>\\n<p>The review describes the classic approach: dissolving the peptide in hydrochloric acid and freeze-drying it, several times over. It reports that this usually reaches up to about 98% exchange after several repetitions, leaves traces of TFA and needs an extra step to remove excess HCl. Because TFA is a strong acid (pKa about 0.5), a weak acid such as acetic acid (pKa about 4.8) cannot displace it in the same way.</p>\\n<p>Other approaches avoid the very low pH of the HCl method. <a href=\"https://pubmed.ncbi.nlm.nih.gov/18035848/\">Roux et al. (2008)</a> compared three routes using the octapeptide lanreotide:</p>\\n<ul>\\n<li>RP-HPLC with a different acid in the mobile phase;</li>\\n<li>an ion-exchange resin loaded with the new counterion;</li>\\n<li>a deprotonation and reprotonation cycle of the amino groups, which requires a basic solution.</li>\\n</ul>\\n<p>The first two gave partial to almost complete exchange for acetate. The third allowed complete removal of TFA.</p>\\n<h2>How labs measure residual TFA</h2>\\n<p>Exchange only matters if it is checked. A 2025 study from ETH Zurich (<a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12389442/\">Erckes et al., 2025, PMC</a>) validated three methods for detecting and quantifying residual TFA against ICH guidelines:</p>\\n<ul>\\n<li><strong>19F-NMR</strong>, which detects fluorine atoms; in a peptide with no fluorinated residues, these come from TFA;</li>\\n<li><strong>FT-IR</strong>, in which TFA has characteristic absorption bands;</li>\\n<li><strong>HPLC with an evaporative light-scattering detector (ELSD)</strong>, a detector that does not rely on UV absorbance.</li>\\n</ul>\\n<p>The same study found that exchanging TFA for chloride did not change peptide purity, but the salt form affected passive membrane permeability in a liposome assay, depending on sequence. The authors call for counterion content to be quantified and specified whenever synthetic peptides are used in assays. Roux et al. likewise used 19F-NMR, 1H-NMR and attenuated total reflectance FT-IR to follow TFA removal.</p>\\n<h2>What a COA should say about the counterion</h2>\\n<p>A certificate of analysis is more informative on this point when it states:</p>\\n<ul>\\n<li>the salt form, for example \"acetate salt\" or \"TFA salt\", rather than only the peptide name;</li>\\n<li>the counterion content, with the method used to measure it;</li>\\n<li>whether a counterion exchange was performed;</li>\\n<li>the net peptide content, so that the counterion share by weight can be estimated.</li>\\n</ul>\\n<p>A COA that gives only HPLC purity and mass says nothing about the counterion. For the wider workflow, see the <a href=\"/guide/how-research-peptides-are-made-and-tested\">guide to how research peptides are made and tested</a>, and for related quality attributes, <a href=\"/articles/synthetic-peptide-impurities\">common impurities in synthetic peptides</a>.</p>\\n<h2>Open questions</h2>\\n<ul>\\n<li>How far the PPAR-α effects reported in mice apply to the TFA levels found in typical cell-culture and animal experiments.</li>\\n<li>Which published peptide findings might be partly explained by the counterion, and how many studies reported their salt form.</li>\\n<li>Whether a standard way of reporting counterion content in research-grade peptide documentation will emerge.</li>\\n</ul>\\n<h2>Supplier documentation</h2>\\n<p>Purita is a store that sells peptides for laboratory research use only. It publishes a certificates page where reports are available for some products; reports are not yet available for every item, so check the page for the specific material.</p>\\n<p><a href=\"https://puritapeptides.com/certificates?link_code=AUTO-200&amp;lid=82\" rel=\"sponsored nofollow\" target=\"_blank\">Purita certificates page</a></p>\\n<p><em>Affiliate disclosure: this is a paid link. DesignPeptide earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</em></p>\\n<h2>Related pages</h2>\\n<ul>\\n<li><a href=\"/\">Peptide design, synthesis and testing, explained</a></li>\\n<li><a href=\"/about\">About DesignPeptide</a></li>\\n<li><a href=\"/guide/how-research-peptides-are-made-and-tested\">How research peptides are made and tested: from synthesis to COA</a></li>\\n<li><a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content: two numbers that are often confused</a></li>\\n<li><a href=\"/articles/synthetic-peptide-impurities\">Common impurities in synthetic peptides and how labs detect them</a></li>\\n</ul>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"Article\", \"headline\": \"TFA, acetate or chloride: why a peptide\\'s counterion matters\", \"description\": \"Why synthetic peptides are often TFA salts, how TFA can affect cell and animal studies, and how labs exchange it for acetate or chloride and measure it.\", \"image\": [\"https://framerusercontent.com/images/Y83bALAPTBgWohX74O0TXBVHs.jpg\"], \"datePublished\": \"2026-10-22\", \"dateModified\": \"2026-10-22\", \"inLanguage\": \"en\", \"author\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide Research Desk\", \"url\": \"https://designpeptide.com/about\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}, \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https://designpeptide.com/articles/peptide-counterions-tfa-acetate-chloride\"}, \"isAccessibleForFree\": true}',\"cover\":{\"src\":\"https://framerusercontent.com/images/Y83bALAPTBgWohX74O0TXBVHs.jpg\",\"alt\":\"Abstract ball-and-stick molecular model in amber tones on a dark background\"},\"excerpt\":\"Most synthetic peptides leave purification as trifluoroacetate (TFA) salts. Why that counterion can skew assays, how labs exchange and measure it, and what a COA should state.\",\"date\":\"22 October 2026\",\"kind\":\"Article\"},\"mass-spectrometry-esi-maldi-peptide-coa\":{\"title\":\"Mass spectrometry on a peptide COA: how ESI-MS and MALDI-TOF confirm identity\",\"path\":\"/articles/mass-spectrometry-esi-maldi-peptide-coa\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<p><em>Published 23 October 2026</em></p>\\n<h2>Why a peptide COA needs both HPLC and MS</h2>\\n<p>On a certificate of analysis (COA) for a synthetic peptide, high-performance liquid chromatography (HPLC) and mass spectrometry (MS) answer two different analytical questions:</p>\\n<ul>\\n<li><strong>HPLC</strong> separates molecules by hydrophobicity on a C18 stationary-phase column (RP-HPLC) and reports the relative area of the ultraviolet-absorbing peaks. It tells the reader whether a sample contains one dominant peak or several, but a retention time alone does not prove which molecule is in that peak.</li>\\n<li><strong>Mass spectrometry</strong> ionises the molecules in the sample and measures their mass-to-charge ratio (<em>m/z</em>). It checks whether the main component has the molecular mass expected from the amino-acid sequence.</li>\\n</ul>\\n<p>Analytical work on falsified or mislabelled research peptides has shown why neither test is sufficient on its own. In a study of seized suspected peptide products, <a href=\"https://pubmed.ncbi.nlm.nih.gov/30029448/\">Janvier et al. (2018)</a> combined liquid chromatography–tandem mass spectrometry (LC-MS/MS) with nuclear magnetic resonance Spectroscopy and found products where the paperwork did not match the actual chemical contents. For how HPLC purity differs from weight-based peptide content, see <a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content</a>.</p>\\n<h2>The two ionisation methods used for peptides</h2>\\n<p>Peptides are polar, non-volatile molecules that decompose if heated into a gas. Modern peptide mass spectrometry relies on two \"soft\" ionisation techniques that transfer intact peptide ions into the gas phase with minimal fragmentation:</p>\\n<table>\\n<thead>\\n<tr>\\n<th>Feature</th>\\n<th>Electrospray ionisation (ESI-MS)</th>\\n<th>Matrix-assisted laser desorption/ionisation (MALDI-TOF)</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr>\\n<td>Physical state of sample</td>\\n<td>Liquid stream, often connected directly to an LC column</td>\\n<td>Co-crystallised dry spot with an UV-absorbing organic matrix</td>\\n</tr>\\n<tr>\\n<td>Typical ion charge states</td>\\n<td>Multiply protonated ions: <code>[M+H]+</code>, <code>[M+2H]2+</code>, <code>[M+3H]3+</code></td>\\n<td>Predominantly singly protonated ions: <code>[M+H]+</code></td>\\n</tr>\\n<tr>\\n<td>Strengths on a routine COA</td>\\n<td>Direct online coupling to RP-HPLC (LC-MS); compact <em>m/z</em> range for larger peptides</td>\\n<td>Simple spectrum with one main <code>[M+H]+</code> peak; tolerant of some buffers and salts</td>\\n</tr>\\n<tr>\\n<td>Common adduct peaks</td>\\n<td>Sodium <code>[M+Na]+</code> (+22 Da), potassium <code>[M+K]+</code> (+38 Da)</td>\\n<td>Matrix clusters at low <em>m/z</em>, sodium and potassium adducts</td>\\n</tr>\\n</tbody>\\n</table>\\n<h3>Electrospray ionisation (ESI-MS)</h3>\\n<p>In ESI-MS, the dissolved peptide is sprayed through a high-voltage capillary, forming charged droplets that evaporate until gas-phase ions enter the mass analyser (<a href=\"https://pubmed.ncbi.nlm.nih.gov/21237305/\">راجعة / review of ESI-MS peptide interactions, PubMed</a>). Because basic side chains (arginine, lysine, histidine) and the N-terminal amine can each pick up a proton in acidic mobile phases, a peptide with three basic sites often appears as a family of peaks—a \"charge envelope\"—corresponding to <code>[M+2H]2+</code>, <code>[M+3H]3+</code> and <code>[M+4H]4+</code>.</p>\\n<p>As general analytical context, each peak in an ESI charge envelope follows the relationship:</p>\\n<ul>\\n<li><code>m/z = (M + z \\xd7 1.0073) / z</code>, where <code>M</code> is the neutral molecular mass of the peptide, <code>z</code> is the integer charge (number of added protons), and <code>1.0073 Da</code> is the mass of a proton.</li>\\n</ul>\\n<p>For example, a peptide with a molecular mass of 1,420.0 Da carrying two protons (<code>z = 2</code>) produces a doubly charged ion <code>[M+2H]2+</code> near <code>m/z = (1420.0 + 2.0) / 2 = 711.0</code>, and a triply charged ion <code>[M+3H]3+</code> near <code>m/z = (1420.0 + 3.0) / 3 = 474.3</code>. When a COA prints an ESI spectrum whose tallest peak is around <code>711</code> while the header lists a molecular weight of <code>1420</code>, that is not a contradiction: the peak is the doubly protonated <code>[M+2H]2+</code> ion.</p>\\n<h3>MALDI-TOF mass spectrometry</h3>\\n<p>In MALDI, the peptide sample is mixed with a small organic acid matrix (such as alpha-cyano-4-hydroxycinnamic acid or sinapinic acid) and dried on a metal target plate. Pulsed ultraviolet laser shots desorb and ionise the matrix and peptide together, and a time-of-flight (TOF) tube measures how fast the ions reach the detector (<a href=\"https://pubmed.ncbi.nlm.nih.gov/24863621/\">kinetic and ion-yield review in <em>Mass Spectrometry Reviews</em>, 2015, PubMed</a>).</p>\\n<p>Because proton transfer in the MALDI plume strongly favours singly charged species, a MALDI-TOF spectrum usually displays a single dominant <code>[M+H]+</code> peak at <code>M + 1</code> Da, sometimes accompanied by smaller sodium (<code>[M+Na]+</code>, <code>M + 23</code> Da) or potassium (<code>[M+K]+</code>, <code>M + 39</code> Da) adduct peaks. MALDI-MS is also widely used with chemical reduction and alkylation to verify disulphide bond pairing in cysteine-containing peptides (<a href=\"https://pubmed.ncbi.nlm.nih.gov/23108743/\">review of disulphide determination by MALDI-MS, PubMed</a>).</p>\\n<h2>Average mass versus monoisotopic mass</h2>\\n<p>A subtle source of confusion when checking a COA is the difference between <strong>monoisotopic mass</strong> and <strong>average (chemical) molecular weight</strong>:</p>\\n<ul>\\n<li><strong>Monoisotopic mass</strong> is calculated using only the most abundant light isotope of each element (<code>12C</code>, <code>1H</code>, <code>14N</code>, <code>16O</code>, <code>32S</code>). High-resolution mass spectrometers resolve the individual isotopic peaks of a peptide and report the monoisotopic <code>m/z</code>.</li>\\n<li><strong>Average mass</strong> weights each element by its natural terrestrial isotope abundance (including <code>13C</code> at 1.1% and <code>34S</code> at 4.2%). Low-resolution instruments that merge the isotopic envelope into a single broad peak, and most chemical catalogue headers, report the average molecular weight.</li>\\n</ul>\\n<p>For a short five-residue peptide the two numbers differ by less than 0.3 Da, whereas for a 30- to 40-residue peptide the average mass is typically 1.5 to 3.0 Da higher than the monoisotopic mass. A thorough COA states which mass definition it uses.</p>\\n<h2>What mass spectrometry on a routine COA cannot detect</h2>\\n<p>A single-stage MS spectrum confirms molecular mass, not complete structural purity. As catalogued in a review of peptide-related impurities by <a href=\"https://pubmed.ncbi.nlm.nih.gov/25044089/\">D\\'Hondt et al. (2014)</a>, several classes of synthesis errors have the exact same molecular mass (isobaric) or nearly the same mass as the target sequence:</p>\\n<ul>\\n<li><strong>Diastereomers (epimers).</strong> If an L-amino acid racemises to a D-amino acid during coupling, the resulting epimer has the exact same elemental formula and molecular mass (<code>Δm = 0 Da</code>). Single-stage MS cannot distinguish it from the target peptide; chromatographic separation is required.</li>\\n<li><strong>Sequence scrambling or isoaspartate rearrangement.</strong> Rearrangement of an Asp-Gly or Asn-Gly linkage through a cyclic aspartimide intermediate to an isoaspartyl residue leaves the mass unchanged (<code>Δm = 0 Da</code>) after hydrolysis.</li>\\n<li><strong>Deamidation.</strong> Conversion of asparagine or glutamine to aspartate or glutamate increases the mass by only <code>+0.984 Da</code>, which overlaps with the natural <code>13C</code> isotope peak on low-resolution instruments.</li>\\n<li><strong>Uncharged or volatile impurities.</strong> Water, inorganic salts and counter-ions such as trifluoroacetate are not quantified by a standard positive-ion peptide mass spectrum. Those require separate assays, as explained in our note on <a href=\"/articles/peptide-counterions-tfa-acetate-chloride\">TFA, acetate and chloride counterions</a> and our overview of <a href=\"/articles/synthetic-peptide-impurities\">synthetic peptide impurities</a>.</li>\\n</ul>\\n<p>To confirm the order of amino acids rather than just the total mass, laboratories use tandem mass spectrometry (MS/MS), which collides the selected precursor ion with an inert gas to generate sequence-defining <code>b</code>- and <code>y</code>-type fragment ions. Validation principles for analytical identification and purity procedures are set out in the ICH Q2(R2) guideline on the <a href=\"https://www.ich.org/page/quality-guidelines\">ICH quality guidelines page</a>.</p>\\n<h2>Checklist for reading the MS section of a COA</h2>\\n<ol>\\n<li><strong>Is the actual mass spectrum shown</strong>, with labelled <em>m/z</em> axes, rather than only a typed \"Conforms\" or single number in a summary table?</li>\\n<li><strong>Are the charge states identified</strong> (<code>[M+H]+</code>, <code>[M+2H]2+</code>, <code>[M+3H]3+</code>) and do they back-calculate to the theoretical molecular weight?</li>\\n<li><strong>Are large unassigned peaks present</strong> that cannot be explained as charge states or sodium/potassium adducts of the main peptide?</li>\\n<li><strong>Does the batch number on the MS printout match</strong> the batch number on the HPLC chromatogram and the vial label?</li>\\n</ol>\\n<p>For the full synthesis-to-testing workflow, see the <a href=\"/guide/how-research-peptides-are-made-and-tested\">guide to how research peptides are made and tested</a>.</p>\\n<h2>Supplier documentation</h2>\\n<p>Purita is a store that sells peptides for laboratory research use only. It publishes a certificates page where reports are available for some products; reports are not yet available for every item, so check the page for the specific material.</p>\\n<p><a href=\"https://puritapeptides.com/certificates?link_code=AUTO-200&amp;lid=82\" rel=\"sponsored nofollow\" target=\"_blank\">Purita certificates page</a></p>\\n<p><em>Affiliate disclosure: this is a paid link. DesignPeptide earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</em></p>\\n<h2>Related pages</h2>\\n<ul>\\n<li><a href=\"/\">Peptide design, synthesis and testing, explained</a></li>\\n<li><a href=\"/about\">About DesignPeptide</a></li>\\n<li><a href=\"/guide/how-research-peptides-are-made-and-tested\">How research peptides are made and tested: from synthesis to COA</a></li>\\n<li><a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content: two numbers that are often confused</a></li>\\n<li><a href=\"/articles/synthetic-peptide-impurities\">Common impurities in synthetic peptides and how labs detect them</a></li>\\n<li><a href=\"/articles/peptide-counterions-tfa-acetate-chloride\">TFA, acetate or chloride: why a peptide\\'s counterion matters</a></li>\\n</ul>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"Article\", \"headline\": \"Mass spectrometry on a peptide COA: how ESI-MS and MALDI-TOF confirm identity\", \"description\": \"How ESI-MS and MALDI-TOF confirm peptide identity on a certificate of analysis, how multiply charged m/z peaks work, and which impurities MS misses.\", \"image\": [\"https://framerusercontent.com/images/ILmCIieRVD2AYdbqxkWo4uArx0.jpg\"], \"datePublished\": \"2026-10-23\", \"dateModified\": \"2026-10-23\", \"inLanguage\": \"en\", \"author\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide Research Desk\", \"url\": \"https://designpeptide.com/about\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}, \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https://designpeptide.com/articles/mass-spectrometry-esi-maldi-peptide-coa\"}, \"isAccessibleForFree\": true}',\"cover\":{\"src\":\"https://framerusercontent.com/images/ILmCIieRVD2AYdbqxkWo4uArx0.jpg\",\"alt\":\"Abstract bar chart and line graph in amber tones on a dark background, suggesting a mass spectrum with m/z peaks\"},\"excerpt\":\"How electrospray ionisation (ESI-MS) and MALDI-TOF mass spectrometry work on a peptide certificate of analysis, how to read m/z peaks, and what MS cannot detect.\",\"date\":\"23 October 2026\",\"kind\":\"Article\"},\"aspartimide-formation-fmoc-spps\":{\"title\":\"Aspartimide formation in Fmoc peptide synthesis: the side reaction behind isoAsp impurities\",\"path\":\"/articles/aspartimide-formation-fmoc-spps\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<p><em>Published 24 October 2026</em></p>\\n<h2>At a glance</h2>\\n<ul>\\n<li><strong>What it is:</strong> a side reaction at aspartic acid (Asp) residues in which the peptide backbone closes onto the Asp side chain to form a five-membered ring, the aspartimide</li>\\n<li><strong>When it happens:</strong> mainly during the repeated basic steps that remove the Fmoc protecting group in Fmoc solid-phase peptide synthesis (SPPS)</li>\\n<li><strong>Why it matters:</strong> the ring opens again to give a mixture of products, some with exactly the same mass as the target peptide</li>\\n<li><strong>Hot spots:</strong> sequences where Asp is followed by glycine (Asp-Gly) are a classic problem, and elevated temperature makes it worse</li>\\n<li><strong>Status in the literature:</strong> a 2025 review in <em>ChemBioChem</em> calls it \"a persistent challenge\" and surveys the main prevention strategies (<a href=\"https://pubmed.ncbi.nlm.nih.gov/40857621/\">Kong et al., 2025</a>)</li>\\n</ul>\\n<h2>Where aspartimide comes from</h2>\\n<p>In Fmoc SPPS, the peptide chain is built on a resin one amino acid at a time. Each new residue carries an Fmoc group on its amine, which is removed with a base, usually piperidine, before the next coupling. Side chains carry acid-labile protecting groups; for aspartic acid the standard choice is a tert-butyl ester, written Asp(OtBu). The overall approach is described in reviews by <a href=\"https://pubmed.ncbi.nlm.nih.gov/2191922/\">Fields and Noble (1990)</a> and <a href=\"https://pubmed.ncbi.nlm.nih.gov/26785684/\">Behrendt, White and Offer (2016)</a>, the latter noting that Fmoc SPPS is now \"the method of choice for peptide synthesis\".</p>\\n<p>The weakness is that the base used to remove Fmoc can also act on the Asp side chain. The nitrogen of the next residue\\'s backbone amide attacks the protected side-chain carbonyl, the ester group leaves, and a five-membered succinimide ring forms. Because Fmoc removal is repeated for every residue added after the Asp, a single aspartic acid near the C-terminus of a long sequence is exposed to base many times. <a href=\"https://pubmed.ncbi.nlm.nih.gov/40857621/\">Kong et al. (2025)</a> describe the process as base-mediated, which is why it is chiefly discussed as an Fmoc-chemistry problem. For how Fmoc and Boc strategies differ, see the <a href=\"/guide/how-research-peptides-are-made-and-tested\">guide to how research peptides are made and tested</a>.</p>\\n<h2>What the ring turns into</h2>\\n<p>The aspartimide is itself an impurity, but it is also reactive. It can open in several ways, and each gives a different product.</p>\\n<table>\\n<thead>\\n<tr>\\n<th>Product</th>\\n<th>How it forms</th>\\n<th>Mass relative to the target peptide</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr>\\n<td>Aspartimide (succinimide)</td>\\n<td>Ring closure with loss of the side-chain protecting group</td>\\n<td>18 Da lighter (loss of water)</td>\\n</tr>\\n<tr>\\n<td>alpha-Asp peptide</td>\\n<td>Water reopens the ring on the original side</td>\\n<td>Same mass; may be the D-epimer</td>\\n</tr>\\n<tr>\\n<td>beta-Asp (isoAsp) peptide</td>\\n<td>Water reopens the ring on the other side, moving the backbone link to the side-chain carbon</td>\\n<td>Same mass</td>\\n</tr>\\n<tr>\\n<td>Piperidide adducts</td>\\n<td>Piperidine from the deprotection solution opens the ring</td>\\n<td>67 Da heavier</td>\\n</tr>\\n<tr>\\n<td>Truncated chain</td>\\n<td>The N-terminal amine attacks the ring, forming a piperazine-2,5-dione and stopping chain growth</td>\\n<td>Shorter sequence</td>\\n</tr>\\n</tbody>\\n</table>\\n<p>The ring\\'s alpha carbon can also lose its stereochemistry, so even the \"correct\" alpha-linked product may come back partly as D-aspartic acid. <a href=\"https://pubmed.ncbi.nlm.nih.gov/26751703/\">Behrendt et al. (2016)</a> report aspartimide suppression together with suppression of aspartic acid epimerisation for this reason.</p>\\n<p>The last row was characterised in detail by <a href=\"https://pubmed.ncbi.nlm.nih.gov/31309675/\">Samson et al. (2019)</a>, who observed significant chain termination at an N-terminal Xaa-Asp-Yaa motif. Using NMR, they showed that only the six-membered piperazine-2,5-dione ring forms, and concluded that hindering aspartimide formation reduces or completely suppresses this termination.</p>\\n<h2>Which sequences are most at risk</h2>\\n<p>Risk depends on the residue after the aspartic acid and on the conditions.</p>\\n<ul>\\n<li><strong>Asp-Gly.</strong> Glycine has no side chain to block the attacking amide, so Asp-Gly is the standard worst case. The model peptide VKDGYI, a fragment of scorpion toxin II, is widely used to test new methods (<a href=\"https://pubmed.ncbi.nlm.nih.gov/26751703/\">Behrendt et al., 2016</a>).</li>\\n<li><strong>Other neighbours.</strong> <a href=\"https://pubmed.ncbi.nlm.nih.gov/26077723/\">Behrendt et al. (2015)</a> also tested variants of the same model with asparagine and arginine after the Asp.</li>\\n<li><strong>Heat.</strong> Microwave and high-temperature synthesis speed up coupling and deprotection, but they also speed up side reactions. <a href=\"https://pubmed.ncbi.nlm.nih.gov/17121420/\">Palasek et al. (2007)</a> reported aspartimide formation and racemisation during microwave Fmoc SPPS, and <a href=\"https://pubmed.ncbi.nlm.nih.gov/36777595/\">Personne et al. (2023)</a> studied the problem at 60 \\xb0C.</li>\\n<li><strong>Long, Asp-rich targets.</strong> Behrendt et al. (2016) used teduglutide, a GLP-2 analogue whose synthesis is complicated by extensive aspartimide formation, as a real-world test case.</li>\\n</ul>\\n<h2>How chemists suppress it</h2>\\n<p>The 2025 review by <a href=\"https://pubmed.ncbi.nlm.nih.gov/40857621/\">Kong et al.</a> groups prevention strategies into four families. The table links each to an example study.</p>\\n<table>\\n<thead>\\n<tr>\\n<th>Strategy</th>\\n<th>Idea</th>\\n<th>Example from the literature</th>\\n</tr>\\n</thead>\\n<tbody>\\n<tr>\\n<td>Bulkier side-chain esters</td>\\n<td>A larger protecting group on the Asp side chain physically blocks the attack</td>\\n<td><a href=\"https://pubmed.ncbi.nlm.nih.gov/26077723/\">Behrendt et al. (2015)</a> compared new trialkylmethyl esters (OEpe, OPhp, OBno) with OtBu and OMpe and found them \"extremely effective\" at minimising aspartimide by-products</td>\\n</tr>\\n<tr>\\n<td>Changing the deprotection solution</td>\\n<td>Adding an acidic additive, or using a milder base, slows the side reaction</td>\\n<td><a href=\"https://pubmed.ncbi.nlm.nih.gov/17121420/\">Palasek et al. (2007)</a> reduced it by adding HOBt or using piperazine instead of piperidine; <a href=\"https://pubmed.ncbi.nlm.nih.gov/36777595/\">Personne et al. (2023)</a> reported that dipropylamine strongly reduced it compared with piperidine at 60 \\xb0C</td>\\n</tr>\\n<tr>\\n<td>Backbone protection</td>\\n<td>Temporarily protecting the amide nitrogen after Asp removes the attacking group</td>\\n<td>Covered as a separate family in <a href=\"https://pubmed.ncbi.nlm.nih.gov/40857621/\">Kong et al. (2025)</a></td>\\n</tr>\\n<tr>\\n<td>Non-ester masking or non-basic deprotection</td>\\n<td>Masking the carboxylic acid with a non-ester group, or replacing Fmoc with a group removed without base</td>\\n<td>Also reviewed in <a href=\"https://pubmed.ncbi.nlm.nih.gov/40857621/\">Kong et al. (2025)</a></td>\\n</tr>\\n</tbody>\\n</table>\\n<p>In the 2016 Asp-Gly study, <a href=\"https://pubmed.ncbi.nlm.nih.gov/26751703/\">Behrendt et al.</a> compared their bulky ester building blocks directly with the common practice of adding acids to the Fmoc deprotection solution, and reported an almost complete reduction in aspartimide formation with the ester approach. No single method is described as universal; Kong et al. conclude that compatible, scalable tactics are still needed for both research and industry.</p>\\n<h2>Reading HPLC and MS data with aspartimide in mind</h2>\\n<p>These by-products behave differently in the two standard tests on a certificate of analysis (COA).</p>\\n<ul>\\n<li><strong>Mass spectrometry.</strong> The aspartimide itself (18 Da lighter) and piperidides (67 Da heavier) show up as extra masses. The alpha- and beta-Asp products and the D-epimer have the same mass as the target, so a mass spectrum alone cannot rule them out. Our article on <a href=\"/articles/mass-spectrometry-esi-maldi-peptide-coa\">mass spectrometry on a peptide COA</a> explains why same-mass impurities are a blind spot.</li>\\n<li><strong>RP-HPLC.</strong> Isomers often elute close to, but not always at the same time as, the main peak. A shoulder or a small neighbouring peak in an Asp-containing sequence is consistent with these products, though it does not identify them. Separating them can require optimised gradients or orthogonal methods.</li>\\n<li><strong>Peptide mapping and NMR.</strong> Distinguishing isoAsp from Asp or confirming the epimer typically needs more specialised work, such as enzymatic digestion with LC-MS/MS or the NMR analysis used by Samson et al.</li>\\n</ul>\\n<p>For the wider list of impurity types and the tests that find them, see <a href=\"/articles/synthetic-peptide-impurities\">common impurities in synthetic peptides</a>. For how a purity figure differs from content by weight, see <a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content</a>.</p>\\n<h2>Limitations of the evidence</h2>\\n<ul>\\n<li>Most studies use short model peptides such as VKDGYI, and the size of the effect varies with sequence, resin, temperature and reagents.</li>\\n<li>Several of the prevention papers come from authors at companies that develop and sell peptide building blocks, as stated in their affiliations.</li>\\n<li>Reported reductions are measured under each paper\\'s own test conditions and are not directly comparable between studies.</li>\\n<li>A COA rarely states which synthesis strategy was used, so a reader usually cannot tell which measures were taken for a given batch.</li>\\n</ul>\\n<h2>Key terms</h2>\\n<ul>\\n<li><strong>Fmoc.</strong> 9-Fluorenylmethoxycarbonyl, an amine protecting group removed with base in each cycle of Fmoc SPPS.</li>\\n<li><strong>Aspartimide.</strong> A five-membered succinimide ring formed between an Asp side chain and the next backbone nitrogen.</li>\\n<li><strong>IsoAsp (beta-Asp).</strong> An aspartic acid residue linked into the backbone through its side-chain carboxyl instead of its alpha carboxyl.</li>\\n<li><strong>Epimerisation.</strong> A change in configuration at one stereocentre, here turning L-aspartic acid into D-aspartic acid.</li>\\n<li><strong>Piperidide.</strong> An adduct formed when piperidine opens the aspartimide ring.</li>\\n</ul>\\n<h2>Supplier documentation</h2>\\n<p>Purita is a store that sells peptides for laboratory research use only. It publishes a certificates page where reports are available for some products; reports are not yet available for every item, so check the page for the specific material.</p>\\n<p><a href=\"https://puritapeptides.com/certificates?link_code=AUTO-200&amp;lid=82\" rel=\"sponsored nofollow\" target=\"_blank\">Purita certificates page</a></p>\\n<p><em>Affiliate disclosure: this is a paid link. DesignPeptide earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</em></p>\\n<h2>Related pages</h2>\\n<ul>\\n<li><a href=\"/\">Peptide design, synthesis and testing, explained</a></li>\\n<li><a href=\"/about\">About DesignPeptide</a></li>\\n<li><a href=\"/guide/how-research-peptides-are-made-and-tested\">How research peptides are made and tested: from synthesis to COA</a></li>\\n<li><a href=\"/articles/synthetic-peptide-impurities\">Common impurities in synthetic peptides and how labs detect them</a></li>\\n<li><a href=\"/articles/mass-spectrometry-esi-maldi-peptide-coa\">Mass spectrometry on a peptide COA: how ESI-MS and MALDI-TOF confirm identity</a></li>\\n<li><a href=\"/articles/hplc-purity-vs-peptide-content\">HPLC purity vs net peptide content: two numbers that are often confused</a></li>\\n</ul>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"Article\", \"headline\": \"Aspartimide formation in Fmoc peptide synthesis: the side reaction behind isoAsp impurities\", \"description\": \"How aspartimide forms at Asp residues in Fmoc SPPS, the isoAsp, epimer and piperidide by-products it causes, ways to prevent it, and how labs detect them.\", \"image\": [\"https://framerusercontent.com/images/8EVzv2uwjqWsccpkwzvrVYNWs.jpg\"], \"datePublished\": \"2026-10-24\", \"dateModified\": \"2026-10-24\", \"inLanguage\": \"en\", \"author\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide Research Desk\", \"url\": \"https://designpeptide.com/about\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}, \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https://designpeptide.com/articles/aspartimide-formation-fmoc-spps\"}, \"isAccessibleForFree\": true}',\"cover\":{\"src\":\"https://framerusercontent.com/images/8EVzv2uwjqWsccpkwzvrVYNWs.jpg\",\"alt\":\"Abstract molecular lattice in amber tones on a dark background, suggesting a five-membered ring in a peptide chain\"},\"excerpt\":\"Why aspartic acid residues are a weak point in Fmoc solid-phase peptide synthesis, which by-products the aspartimide ring produces, how chemists suppress it, and what it means when reading HPLC and MS data.\",\"date\":\"24 October 2026\",\"kind\":\"Article\"},\"affiliate\":{\"title\":\"Affiliate disclosure\",\"path\":\"/affiliate-disclosure\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<p>DesignPeptide is a research-only reference site. It has one commercial relationship: an affiliate arrangement with Purita, a store that sells peptides for laboratory research use only.</p>\\n<h2>How the paid links work</h2>\\n<p>Some pages contain links to Purita\\'s website that carry a tracking code. If a purchase is made after following one of these links, DesignPeptide may earn a commission. The price paid by the buyer is the same with or without the link.</p>\\n<p>Each paid link is followed by a short \"Affiliate disclosure\" note on the page, and is marked in the page code as sponsored.</p>\\n<h2>What the relationship does not change</h2>\\n<ul>\\n<li>Purita does not review, approve or edit any content on this site.</li>\\n<li>The commission does not affect which studies or regulatory records are reported, or how they are described.</li>\\n<li>A link is not an endorsement and is not a statement about the quality of any product.</li>\\n</ul>\\n<h2>What this site says about Purita</h2>\\n<p>Statements about Purita are limited to what can be checked on Purita\\'s own website. Its product pages carry the label \"For Research Use Only. Not for human or animal administration.\", and it publishes a certificates page with batch documentation for some products.</p>\\n<h2>Research use only</h2>\\n<p>Products sold by research suppliers are intended for laboratory research. Nothing on this site describes or encourages human or animal use. See the <a href=\"/research-only\">research-only notice</a>.</p>\\n<h2>Contact</h2>\\n<p>Questions about this disclosure: <a href=\"mailto:info@zvezdaff.com\">info@zvezdaff.com</a>.</p>\\n<p>Last updated: 21 October 2026.</p>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"WebPage\", \"name\": \"Affiliate disclosure\", \"description\": \"How DesignPeptide earns money: paid links to Purita, a research-use-only supplier, and what that relationship does and does not change.\", \"url\": \"https://designpeptide.com/affiliate-disclosure\", \"dateModified\": \"2026-10-21\", \"inLanguage\": \"en\", \"isPartOf\": {\"@type\": \"WebSite\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}}',\"cover\":{\"src\":\"https://framerusercontent.com/images/mdzoy8Gh068mitm5v1pSRuPnhM.jpg\",\"alt\":\"Abstract bar chart and line graph, cover image for affiliate disclosure\"},\"excerpt\":\"How DesignPeptide earns money: paid links to Purita, a research-use-only supplier, and what that relationship does and does not change.\",\"kind\":\"Site information\"},\"research\":{\"title\":\"Research-only notice\",\"path\":\"/research-only\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<p>DesignPeptide summarises published research and public regulatory records about peptides studied in laboratories. All content is provided for research and educational purposes only. It is not intended for human use and it is not medical advice.</p>\\n<h2>What this site does not provide</h2>\\n<ul>\\n<li>Medical advice, diagnosis or guidance on the use of any substance in people or animals.</li>\\n<li>Instructions on preparation, administration, amounts or schedules.</li>\\n<li>Claims that any research compound is safe or effective in people.</li>\\n</ul>\\n<h2>Research-use-only materials</h2>\\n<p>Materials labelled \"research use only\" are intended for laboratory research. They are not approved medicines. A supplier\\'s certificate of analysis describes a batch; it says nothing about suitability for any use. Where a compound also exists as a regulator-approved product, that approval covers the specific product and its labelled use only.</p>\\n<h2>Evidence and its limits</h2>\\n<p>Many findings summarised here come from cell or animal studies, which often do not carry over to people. Each page links its primary sources so that readers can check the original records.</p>\\n<h2>Health questions</h2>\\n<p>This site does not answer individual health questions.</p>\\n<h2>Paid links</h2>\\n<p>Some pages carry paid links to a research supplier. See the <a href=\"/affiliate-disclosure\">affiliate disclosure</a>.</p>\\n<h2>Contact</h2>\\n<p>Corrections and questions: <a href=\"mailto:info@zvezdaff.com\">info@zvezdaff.com</a>.</p>\\n<p>Last updated: 21 October 2026.</p>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"WebPage\", \"name\": \"Research-only notice\", \"description\": \"DesignPeptide content is for research and educational purposes only. It is not intended for human use and is not medical advice.\", \"url\": \"https://designpeptide.com/research-only\", \"dateModified\": \"2026-10-21\", \"inLanguage\": \"en\", \"isPartOf\": {\"@type\": \"WebSite\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}}',\"cover\":{\"src\":\"https://framerusercontent.com/images/WspmYJC33iyiEYMxwdndKapyaM.jpg\",\"alt\":\"Abstract hexagonal molecular lattice, cover image for research-only notice\"},\"excerpt\":\"DesignPeptide content is for research and educational purposes only. It is not intended for human use and is not medical advice.\",\"kind\":\"Site information\"},\"privacy\":{\"title\":\"Privacy policy\",\"path\":\"/privacy\",\"html\":'<p><em>Prepared by: Research Desk. Sources are linked for verification.</em></p>\\n<p>This policy explains what data DesignPeptide handles and why.</p>\\n<h2>Who runs this site</h2>\\n<p>DesignPeptide is published by the DesignPeptide Research Desk. Contact: <a href=\"mailto:info@zvezdaff.com\">info@zvezdaff.com</a>.</p>\\n<h2>Data collected</h2>\\n<p>The site has no accounts, comment forms or newsletter signups, and it does not ask visitors for personal information. It does not use advertising cookies and does not sell personal data.</p>\\n<p>The site is hosted on Framer. Like any web host, Framer processes the technical data needed to deliver pages, such as IP address, browser type and the pages requested, and it may produce aggregated visit statistics.</p>\\n<h2>Links to other websites</h2>\\n<p>Pages link to external sources such as PubMed and the FDA, and to Purita through paid links. A paid link carries a tracking code that Purita\\'s website can record when the link is followed. Other websites apply their own privacy policies.</p>\\n<h2>Email</h2>\\n<p>Messages sent to info@zvezdaff.com are used only to reply. Addresses are not added to any mailing list or shared.</p>\\n<h2>Access and deletion</h2>\\n<p>Requests to access, correct or delete personal data can be sent to info@zvezdaff.com.</p>\\n<h2>Changes</h2>\\n<p>Last updated: 21 October 2026.</p>',\"jsonld\":'{\"@context\": \"https://schema.org\", \"@type\": \"WebPage\", \"name\": \"Privacy policy\", \"description\": \"What data DesignPeptide handles: no accounts or forms, hosting by Framer, paid-link tracking codes and how to contact the Research Desk.\", \"url\": \"https://designpeptide.com/privacy\", \"dateModified\": \"2026-10-21\", \"inLanguage\": \"en\", \"isPartOf\": {\"@type\": \"WebSite\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"DesignPeptide\", \"url\": \"https://designpeptide.com/\", \"email\": \"info@zvezdaff.com\"}}',\"cover\":{\"src\":\"https://framerusercontent.com/images/iM4NJG9Mdt175YxQxi8MB8Cq20.jpg\",\"alt\":\"Abstract network of connected nodes, cover image for privacy policy\"},\"excerpt\":\"What data DesignPeptide handles: no accounts or forms, hosting by Framer, paid-link tracking codes and how to contact the Research Desk.\",\"kind\":\"Site information\"},\"notfound\":{\"title\":\"Page not found\",\"path\":\"/404\",\"html\":'<p>The page you were looking for does not exist or has moved. The research pages below are a good place to continue, or go back to the <a href=\"/\">homepage</a>.</p>',\"jsonld\":\"\",\"cover\":{\"src\":\"\",\"alt\":\"\"},\"excerpt\":\"\",\"kind\":\"\"}};const CARDS=[{\"path\":\"/guide/how-research-peptides-are-made-and-tested\",\"title\":\"How research peptides are made and tested: from synthesis to COA\",\"excerpt\":\"How synthetic research peptides are assembled and analysed, and what each section of a certificate of analysis records.\",\"key\":\"guide\",\"kind\":\"Guide\"},{\"path\":\"/articles/hplc-purity-vs-peptide-content\",\"title\":\"HPLC purity vs net peptide content: two numbers that are often confused\",\"excerpt\":\"In an illustrative example, a batch shows 98% HPLC purity yet only 80% peptide by weight. This page explains why the two figures differ and how to read each on a COA.\",\"key\":\"hplc-purity-vs-peptide-content\",\"kind\":\"Article\"},{\"path\":\"/articles/synthetic-peptide-impurities\",\"title\":\"Common impurities in synthetic peptides and how labs detect them\",\"excerpt\":\"The impurities that arise in synthetic peptides, the analytical methods that reveal them, and the narrow scope of the FDA's 2021 impurity thresholds.\",\"key\":\"synthetic-peptide-impurities\",\"kind\":\"Article\"},{\"path\":\"/articles/peptide-counterions-tfa-acetate-chloride\",\"title\":\"TFA, acetate or chloride: why a peptide's counterion matters\",\"excerpt\":\"Most synthetic peptides leave purification as trifluoroacetate (TFA) salts. Why that counterion can skew assays, how labs exchange and measure it, and what a COA should state.\",\"key\":\"peptide-counterions-tfa-acetate-chloride\",\"kind\":\"Article\"},{\"path\":\"/articles/mass-spectrometry-esi-maldi-peptide-coa\",\"title\":\"Mass spectrometry on a peptide COA: how ESI-MS and MALDI-TOF confirm identity\",\"excerpt\":\"How electrospray ionisation (ESI-MS) and MALDI-TOF mass spectrometry work on a peptide certificate of analysis, how to read m/z peaks, and what MS cannot detect.\",\"key\":\"mass-spectrometry-esi-maldi-peptide-coa\",\"kind\":\"Article\"},{\"path\":\"/articles/aspartimide-formation-fmoc-spps\",\"title\":\"Aspartimide formation in Fmoc peptide synthesis: the side reaction behind isoAsp impurities\",\"excerpt\":\"Why aspartic acid residues are a weak point in Fmoc solid-phase peptide synthesis, which by-products the aspartimide ring produces, how chemists suppress it, and what it means when reading HPLC and MS data.\",\"key\":\"aspartimide-formation-fmoc-spps\",\"kind\":\"Article\"}];const SHORT_LINE=\"Not medical advice. This page reports published research and regulatory records for information only.\";const NOTICES=[\"Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.\",\"Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.\"];const CSS=`\n.ps{color:var(--ink);background:var(--bg);width:100%;line-height:1.65;font-size:17px;-webkit-font-smoothing:antialiased}\n.ps *{box-sizing:border-box}\n.ps a{color:var(--link);text-decoration:underline;text-underline-offset:2px}\n.ps .wrap{max-width:800px;margin:0 auto;padding:0 20px}\n.ps header .wrap{display:flex;flex-wrap:wrap;align-items:center;justify-content:space-between;gap:10px 24px;padding-top:16px;padding-bottom:16px}\n.ps .brand{font-weight:700;font-size:19px;text-decoration:none}\n.ps nav ul{list-style:none;display:flex;flex-wrap:wrap;gap:6px 18px;margin:0;padding:0}\n.ps nav a{color:var(--muted);text-decoration:none;font-size:15px}\n.ps nav a[aria-current=page]{font-weight:600;color:var(--ink)}\n.ps main{padding:36px 0 56px}\n.ps h1{font-size:34px;line-height:1.2;letter-spacing:-.01em;margin:6px 0 14px}\n.ps h2{font-size:23px;line-height:1.3;margin:38px 0 12px}\n.ps h3{font-size:19px;margin:26px 0 8px}\n.ps p,.ps ul,.ps ol{margin:0 0 16px}.ps ul,.ps ol{padding-left:22px}.ps li{margin:0 0 8px}\n.ps em{color:var(--muted)}\n.ps .meta{font-size:14px;color:var(--muted);margin:0 0 18px}\n.ps .lede{font-size:19px;color:var(--muted)}\n.ps .tbl{overflow-x:auto;margin:0 0 20px}\n.ps table{width:100%;border-collapse:collapse;font-size:15px}\n.ps th,.ps td{text-align:left;vertical-align:top;padding:10px 12px;border-bottom:1px solid var(--line)}\n.ps th{background:var(--soft);font-weight:600}\n.ps hr{border:0;border-top:1px solid var(--line);margin:32px 0}\n.ps .cover{margin:0 0 26px}\n.ps img.ci{width:100%;height:auto;aspect-ratio:16/9;object-fit:cover;display:block;border-radius:8px;background:var(--head)}\n.ps .cards{display:grid;grid-template-columns:repeat(2,minmax(0,1fr));gap:24px;margin:10px 0 34px}\n.ps .card{display:block}\n.ps .card h3{font-size:18px;line-height:1.35;margin:12px 0 6px;color:var(--ink)}\n.ps .card h3 a{color:var(--ink);text-decoration:none}.ps .card h3 a:hover{text-decoration:underline}\n.ps .card p{font-size:15px;color:var(--muted);margin:0}\n.ps footer{background:var(--soft);border-top:1px solid var(--line);color:var(--muted);font-size:14px;padding:28px 0 36px}\n.ps footer ul{list-style:none;display:flex;flex-wrap:wrap;gap:6px 18px;margin:0 0 18px;padding:0}\n.ps footer a{color:var(--muted)}\n.ps footer p{margin:0 0 10px}\n@media (max-width:640px){.ps .cards{grid-template-columns:1fr}}\n@media (max-width:600px){.ps{font-size:16px}.ps h1{font-size:28px}.ps h2{font-size:20px}.ps main{padding:26px 0 40px}}\n\n.dp{--ink:#22201c;--muted:#5d574d;--line:#e2dccf;--bg:#fdfcf8;--soft:#f6f2e8;--link:#9a4d06;--accent:#c27a1a;--head:#f6f2e8;--headink:#22201c;\n font-family:\"Avenir Next\",\"Segoe UI\",system-ui,-apple-system,Roboto,Arial,sans-serif}\n.dp header{background-color:var(--head);background-image:linear-gradient(rgba(194,122,26,.12) 1px,transparent 1px),linear-gradient(90deg,rgba(194,122,26,.12) 1px,transparent 1px);background-size:22px 22px;border-top:6px solid var(--ink);border-bottom:1px solid var(--line)}\n.dp header .brand{color:var(--ink);text-transform:uppercase;letter-spacing:.08em;font-size:17px}\n.dp .kicker{font-size:12px;text-transform:uppercase;letter-spacing:.1em;color:var(--link);font-weight:700}\n.dp h2{text-transform:uppercase;letter-spacing:.04em;font-size:19px;border-bottom:2px solid var(--accent);padding-bottom:6px;display:inline-block}\n.dp .card{border:1px solid var(--line);background:#fff;padding:0 0 14px}.dp .card h3,.dp .card p{padding:0 14px}\n.dp .card img{border-radius:0}\n`;function wrapTables(html){return html.replace(/<table>/g,'<div class=\"tbl\"><table>').replace(/<\\/table>/g,\"</table></div>\");}function Cards({items,heading}){if(!items.length)return null;return /*#__PURE__*/_jsxs(\"section\",{\"aria-label\":heading,children:[/*#__PURE__*/_jsx(\"h2\",{children:heading}),/*#__PURE__*/_jsx(\"div\",{className:\"cards\",children:items.map(c=>{const cv=(PAGES[c.key]||{}).cover||{};return /*#__PURE__*/_jsxs(\"article\",{className:\"card\",children:[/*#__PURE__*/_jsx(\"a\",{href:c.path,\"aria-hidden\":\"true\",tabIndex:-1,children:/*#__PURE__*/_jsx(\"img\",{className:\"ci\",src:cv.src,alt:cv.alt,width:1600,height:900,loading:\"lazy\"})}),/*#__PURE__*/_jsxs(\"div\",{children:[/*#__PURE__*/_jsx(\"h3\",{children:/*#__PURE__*/_jsx(\"a\",{href:c.path,children:c.title})}),/*#__PURE__*/_jsx(\"p\",{children:c.excerpt})]})]},c.path);})})]});}/**\n * @framerSupportedLayoutWidth any-prime\n * @framerSupportedLayoutHeight auto\n * @framerIntrinsicWidth 1200\n */export default function SitePage({page=\"home\"}){const p=PAGES[page]||PAGES.home;const isHome=page===\"home\";const more=page===\"notfound\"?CARDS:CARDS.filter(c=>c.path!==p.path);return /*#__PURE__*/_jsxs(\"div\",{className:\"ps dp\",children:[/*#__PURE__*/_jsx(\"style\",{children:CSS}),/*#__PURE__*/_jsx(\"header\",{children:/*#__PURE__*/_jsxs(\"div\",{className:\"wrap\",children:[/*#__PURE__*/_jsx(\"a\",{className:\"brand\",href:\"/\",children:SITE}),/*#__PURE__*/_jsx(\"nav\",{\"aria-label\":\"Main\",children:/*#__PURE__*/_jsx(\"ul\",{children:NAV.map(([href,label])=>/*#__PURE__*/_jsx(\"li\",{children:/*#__PURE__*/_jsx(\"a\",{href:href,\"aria-current\":href===p.path?\"page\":undefined,children:label})},href))})})]})}),/*#__PURE__*/_jsx(\"main\",{children:/*#__PURE__*/_jsxs(\"article\",{className:\"wrap\",children:[p.jsonld?/*#__PURE__*/_jsx(\"script\",{type:\"application/ld+json\",dangerouslySetInnerHTML:{__html:p.jsonld}}):null,/*#__PURE__*/_jsx(\"div\",{className:\"kicker\",children:p.kind||KICKER}),/*#__PURE__*/_jsx(\"h1\",{children:p.title}),p.date?/*#__PURE__*/_jsxs(\"p\",{className:\"meta\",children:[\"Published \",p.date,\" \\xb7 \",SITE,\" Research Desk\"]}):null,isHome&&p.excerpt?/*#__PURE__*/_jsx(\"p\",{className:\"lede\",children:p.excerpt}):null,p.cover&&p.cover.src?/*#__PURE__*/_jsx(\"figure\",{className:\"cover\",children:/*#__PURE__*/_jsx(\"img\",{className:\"ci\",src:p.cover.src,alt:p.cover.alt,width:1600,height:900})}):null,isHome?/*#__PURE__*/_jsx(Cards,{items:CARDS,heading:\"Start here\"}):null,/*#__PURE__*/_jsx(\"div\",{dangerouslySetInnerHTML:{__html:wrapTables(p.html)}}),!isHome?/*#__PURE__*/_jsx(Cards,{items:more,heading:page===\"notfound\"?\"Research pages\":\"More from \"+SITE}):null]})}),/*#__PURE__*/_jsx(\"footer\",{children:/*#__PURE__*/_jsxs(\"div\",{className:\"wrap\",children:[/*#__PURE__*/_jsx(\"ul\",{children:FOOTER_NAV.map(([href,label])=>/*#__PURE__*/_jsx(\"li\",{children:/*#__PURE__*/_jsx(\"a\",{href:href,children:label})},href))}),/*#__PURE__*/_jsxs(\"p\",{children:[SITE,\" \\xb7 Contact: \",/*#__PURE__*/_jsx(\"a\",{href:\"mailto:info@zvezdaff.com\",children:\"info@zvezdaff.com\"})]}),/*#__PURE__*/_jsx(\"p\",{children:/*#__PURE__*/_jsx(\"em\",{children:SHORT_LINE})}),/*#__PURE__*/_jsx(\"p\",{children:NOTICES[0]}),/*#__PURE__*/_jsx(\"p\",{children:NOTICES[1]})]})})]});}addPropertyControls(SitePage,{page:{type:ControlType.Enum,title:\"Page\",options:[\"home\",\"about\",\"guide\",\"hplc-purity-vs-peptide-content\",\"synthetic-peptide-impurities\",\"peptide-counterions-tfa-acetate-chloride\",\"mass-spectrometry-esi-maldi-peptide-coa\",\"aspartimide-formation-fmoc-spps\",\"affiliate\",\"research\",\"privacy\",\"notfound\"],optionTitles:[\"Peptide design, synthesis and testing, explained\",\"About DesignPeptide\",\"How research peptides are made and tested: from synthesis to COA\",\"HPLC purity vs net peptide content: two numbers that are often confused\",\"Common impurities in synthetic peptides and how labs detect them\",\"TFA, acetate or chloride: why a peptide's counterion matters\",\"Mass spectrometry on a peptide COA: how ESI-MS and MALDI-TOF confirm identity\",\"Aspartimide formation in Fmoc peptide synthesis: the side reaction behind isoAsp impurities\",\"Affiliate disclosure\",\"Research-only notice\",\"Privacy policy\",\"Page not found\"],defaultValue:\"home\"}});\nexport const __FramerMetadata__ = {\"exports\":{\"default\":{\"type\":\"reactComponent\",\"name\":\"SitePage\",\"slots\":[],\"annotations\":{\"framerSupportedLayoutHeight\":\"auto\",\"framerIntrinsicWidth\":\"1200\",\"framerContractVersion\":\"1\",\"framerSupportedLayoutWidth\":\"any-prime\"}},\"__FramerMetadata__\":{\"type\":\"variable\"}}}\n//# sourceMappingURL=./SitePage.map"],"mappings":"mKA+CE,SAAS,EAAW,EAAK,CAAC,OAAO,EAAK,QAAQ,WAAW,0BAA0B,CAAC,CAAC,QAAQ,aAAa,gBAAgB,CAAE,CAAC,SAAS,EAAM,CAAC,QAAM,WAAS,CAA8B,OAAzB,EAAM,OAAuC,EAAM,UAAU,CAAC,aAAa,EAAQ,SAAS,CAAc,EAAK,KAAK,CAAC,SAAS,CAAO,CAAC,EAAe,EAAK,MAAM,CAAC,UAAU,QAAQ,SAAS,EAAM,IAAI,GAAG,CAAC,IAAM,GAAI,EAAMA,EAAE,MAAM,CAAC,EAAA,CAAG,OAAO,CAAC,EAAE,OAAoB,EAAM,UAAU,CAAC,UAAU,OAAO,SAAS,CAAc,EAAK,IAAI,CAAC,KAAKA,EAAE,KAAK,cAAc,OAAO,SAAS,GAAG,SAAsB,EAAK,MAAM,CAAC,UAAU,KAAK,IAAI,EAAG,IAAI,IAAI,EAAG,IAAI,MAAM,KAAK,OAAO,IAAI,QAAQ,MAAM,CAAC,CAAC,CAAC,EAAe,EAAM,MAAM,CAAC,SAAS,CAAc,EAAK,KAAK,CAAC,SAAsB,EAAK,IAAI,CAAC,KAAKA,EAAE,KAAK,SAASA,EAAE,KAAK,CAAC,CAAC,CAAC,EAAe,EAAK,IAAI,CAAC,SAASA,EAAE,OAAO,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,EAAEA,EAAE,IAAI,CAAE,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,EAA5oB,IAA8oB,CAIl0B,SAAwB,EAAS,CAAC,OAAK,QAAQ,CAAC,IAAMC,EAAE,EAAM,IAAO,EAAM,KAAW,EAAO,IAAO,OAAa,EAAK,IAAO,WAAW,EAAM,EAAM,OAAO,GAAG,EAAE,OAAOA,EAAE,IAAI,EAAE,OAAoB,EAAM,MAAM,CAAC,UAAU,QAAQ,SAAS,CAAc,EAAK,QAAQ,CAAC,SAAS,CAAG,CAAC,EAAe,EAAK,SAAS,CAAC,SAAsB,EAAM,MAAM,CAAC,UAAU,OAAO,SAAS,CAAc,EAAK,IAAI,CAAC,UAAU,QAAQ,KAAK,IAAI,SAAS,CAAI,CAAC,EAAe,EAAK,MAAM,CAAC,aAAa,OAAO,SAAsB,EAAK,KAAK,CAAC,SAAS,EAAI,KAAK,CAAC,EAAK,KAAsB,EAAK,KAAK,CAAC,SAAsB,EAAK,IAAI,CAAM,OAAK,eAAe,IAAOA,EAAE,KAAK,OAAO,IAAA,GAAU,SAAS,CAAK,CAAC,CAAC,EAAE,CAAI,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,EAAe,EAAK,OAAO,CAAC,SAAsB,EAAM,UAAU,CAAC,UAAU,OAAO,SAAS,CAACA,EAAE,OAAoB,EAAK,SAAS,CAAC,KAAK,sBAAsB,wBAAwB,CAAC,OAAOA,EAAE,MAAM,CAAC,CAAC,EAAE,KAAkB,EAAK,MAAM,CAAC,UAAU,SAAS,SAASA,EAAE,MAAM,CAAM,CAAC,EAAe,EAAK,KAAK,CAAC,SAASA,EAAE,KAAK,CAAC,EAAEA,EAAE,KAAkB,EAAM,IAAI,CAAC,UAAU,OAAO,SAAS,CAAC,aAAaA,EAAE,KAAK,MAAS,EAAK,gBAAgB,CAAC,CAAC,EAAE,KAAK,GAAQA,EAAE,QAAqB,EAAK,IAAI,CAAC,UAAU,OAAO,SAASA,EAAE,OAAO,CAAC,EAAE,KAAKA,EAAE,OAAOA,EAAE,MAAM,IAAiB,EAAK,SAAS,CAAC,UAAU,QAAQ,SAAsB,EAAK,MAAM,CAAC,UAAU,KAAK,IAAIA,EAAE,MAAM,IAAI,IAAIA,EAAE,MAAM,IAAI,MAAM,KAAK,OAAO,GAAG,CAAC,CAAC,CAAC,EAAE,KAAK,EAAoB,EAAK,EAAM,CAAC,MAAM,EAAM,QAAQ,YAAY,CAAC,EAAE,KAAkB,EAAK,MAAM,CAAC,wBAAwB,CAAC,OAAO,EAAWA,EAAE,IAAI,CAAC,CAAC,CAAC,EAAG,EAA0G,KAAtF,EAAK,EAAM,CAAC,MAAM,EAAK,QAAQ,IAAO,WAAW,iBAAiB,yBAAiB,CAAC,CAAM,CAAC,CAAC,CAAC,CAAC,EAAe,EAAK,SAAS,CAAC,SAAsB,EAAM,MAAM,CAAC,UAAU,OAAO,SAAS,CAAc,EAAK,KAAK,CAAC,SAAS,EAAW,KAAK,CAAC,EAAK,KAAsB,EAAK,KAAK,CAAC,SAAsB,EAAK,IAAI,CAAM,OAAK,SAAS,CAAK,CAAC,CAAC,EAAE,CAAI,CAAC,CAAC,CAAC,EAAe,EAAM,IAAI,CAAC,SAAS,CAAC,EAAK,eAA+B,EAAK,IAAI,CAAC,KAAK,2BAA2B,SAAS,mBAAmB,CAAC,CAAC,CAAC,CAAC,EAAe,EAAK,IAAI,CAAC,SAAsB,EAAK,KAAK,CAAC,SAAS,CAAU,CAAC,CAAC,CAAC,EAAe,EAAK,IAAI,CAAC,SAAS,EAAQ,EAAE,CAAC,EAAe,EAAK,IAAI,CAAC,SAAS,EAAQ,EAAE,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,CAAC,CAAE,mCAjD/nE,IAAoD,EAAO,EAAK,gBAAsB,EAAO,8CAAoD,EAAI,CAAC,CAAC,IAAI,MAAM,EAAE,CAAC,mDAAmD,OAAO,EAAE,CAAC,SAAS,OAAO,CAAC,EAAQ,EAAW,CAAC,CAAC,IAAI,MAAM,EAAE,CAAC,mDAAmD,2CAA2C,EAAE,CAAC,2CAA2C,oCAAoC,EAAE,CAAC,yCAAyC,kEAAkE,EAAE,CAAC,qDAAqD,0BAA0B,EAAE,CAAC,oDAAoD,oCAAoC,EAAE,CAAC,4CAA4C,iDAAiD,EAAE,CAAC,SAAS,OAAO,EAAE,CAAC,wBAAwB,sBAAsB,EAAE,CAAC,iBAAiB,sBAAsB,EAAE,CAAC,WAAW,SAAS,CAAC,EAAQ,EAAM,CAAC,KAAO,CAAC,MAAQ,mDAAmD,KAAO,IAAI,KAAO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;OAA8yL,OAAS,mpBAAmpB,MAAQ,CAAC,IAAM,sEAAsE,IAAM,4FAA4F,EAAE,QAAU,+IAA+I,KAAO,EAAE,EAAE,MAAQ,CAAC,MAAQ,sBAAsB,KAAO,SAAS,KAAO;;;;;;;;;;;;;;;;;;;;;OAAq9G,OAAS,wjBAAwjB,MAAQ,CAAC,IAAM,sEAAsE,IAAM,uFAAuF,EAAE,QAAU,4KAA4K,KAAO,OAAO,EAAE,MAAQ,CAAC,MAAQ,mEAAmE,KAAO,mDAAmD,KAAO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;OAAogV,OAAS,g2BAAg2B,MAAQ,CAAC,IAAM,sEAAsE,IAAM,oGAAoG,EAAE,QAAU,0HAA0H,KAAO,kBAAkB,KAAO,OAAO,EAAE,iCAAiC,CAAC,MAAQ,0EAA0E,KAAO,2CAA2C,KAAO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;OAAitQ,OAAS,41BAA41B,MAAQ,CAAC,IAAM,sEAAsE,IAAM,0FAA0F,EAAE,QAAU,yKAAyK,KAAO,kBAAkB,KAAO,SAAS,EAAE,+BAA+B,CAAC,MAAQ,mEAAmE,KAAO,yCAAyC,KAAO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;OAAm/S,OAAS,m2BAAm2B,MAAQ,CAAC,IAAM,qEAAqE,IAAM,4GAA4G,EAAE,QAAU,wJAAwJ,KAAO,kBAAkB,KAAO,SAAS,EAAE,2CAA2C,CAAC,MAAQ,+DAA+D,KAAO,qDAAqD,KAAO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;OAA89Q,OAAS,y2BAA02B,MAAQ,CAAC,IAAM,qEAAqE,IAAM,6EAA6E,EAAE,QAAU,kLAAkL,KAAO,kBAAkB,KAAO,SAAS,EAAE,0CAA0C,CAAC,MAAQ,gFAAgF,KAAO,oDAAoD,KAAO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;OAAkgW,OAAS,s3BAAs3B,MAAQ,CAAC,IAAM,sEAAsE,IAAM,kHAAkH,EAAE,QAAU,oKAAoK,KAAO,kBAAkB,KAAO,SAAS,EAAE,kCAAkC,CAAC,MAAQ,8FAA8F,KAAO,4CAA4C,KAAO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;OAAo1X,OAAS,i4BAAi4B,MAAQ,CAAC,IAAM,qEAAqE,IAAM,oHAAoH,EAAE,QAAU,iNAAiN,KAAO,kBAAkB,KAAO,SAAS,EAAE,UAAY,CAAC,MAAQ,uBAAuB,KAAO,wBAAwB,KAAO;;;;;;;;;;;;;;;;;uCAAgtD,OAAS,kkBAAkkB,MAAQ,CAAC,IAAM,sEAAsE,IAAM,yEAAyE,EAAE,QAAU,0IAA0I,KAAO,kBAAkB,EAAE,SAAW,CAAC,MAAQ,uBAAuB,KAAO,iBAAiB,KAAO;;;;;;;;;;;;;;;;;;uCAAmnD,OAAS,ojBAAojB,MAAQ,CAAC,IAAM,sEAAsE,IAAM,4EAA4E,EAAE,QAAU,mIAAmI,KAAO,kBAAkB,EAAE,QAAU,CAAC,MAAQ,iBAAiB,KAAO,WAAW,KAAO;;;;;;;;;;;;;;uCAAo1C,OAAS,gjBAAgjB,MAAQ,CAAC,IAAM,sEAAsE,IAAM,qEAAqE,EAAE,QAAU,2IAA2I,KAAO,kBAAkB,EAAE,SAAW,CAAC,MAAQ,iBAAiB,KAAO,OAAO,KAAO,uKAAuK,OAAS,GAAG,MAAQ,CAAC,IAAM,GAAG,IAAM,EAAE,EAAE,QAAU,GAAG,KAAO,EAAE,CAAC,EAAQ,EAAM,CAAC,CAAC,KAAO,mDAAmD,MAAQ,mEAAmE,QAAU,0HAA0H,IAAM,QAAQ,KAAO,OAAO,EAAE,CAAC,KAAO,2CAA2C,MAAQ,0EAA0E,QAAU,yKAAyK,IAAM,iCAAiC,KAAO,SAAS,EAAE,CAAC,KAAO,yCAAyC,MAAQ,mEAAmE,QAAU,wJAAwJ,IAAM,+BAA+B,KAAO,SAAS,EAAE,CAAC,KAAO,qDAAqD,MAAQ,+DAA+D,QAAU,kLAAkL,IAAM,2CAA2C,KAAO,SAAS,EAAE,CAAC,KAAO,oDAAoD,MAAQ,gFAAgF,QAAU,oKAAoK,IAAM,0CAA0C,KAAO,SAAS,EAAE,CAAC,KAAO,4CAA4C,MAAQ,8FAA8F,QAAU,iNAAiN,IAAM,kCAAkC,KAAO,SAAS,CAAC,EAAQ,EAAW,wGAA8G,EAAQ,CAAC,iKAAiK,+HAA+H,EAAQ,EAAI;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;EAiDzsxF,EAAoB,EAAS,CAAC,KAAK,CAAC,KAAK,EAAY,KAAK,MAAM,OAAO,QAAQ,CAAC,OAAO,QAAQ,QAAQ,iCAAiC,+BAA+B,2CAA2C,0CAA0C,kCAAkC,YAAY,WAAW,UAAU,UAAU,EAAE,aAAa,CAAC,mDAAmD,sBAAsB,mEAAmE,0EAA0E,mEAAmE,+DAA+D,gFAAgF,8FAA8F,uBAAuB,uBAAuB,iBAAiB,gBAAgB,EAAE,aAAa,MAAM,CAAC,CAAC"}